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Abstract 
 
The currently available malaria drugs in the market are unsatisfactory in many 
respects. Shortcomings include costly treatments, toxicity and various side 
effects. The rapid rise of resistant strains of Plasmodium falciparum, 
particularly in South-East Asia, has rendered even the most promising 
treatment regimens ineffective. Therefore, there is an urgent need to explore 
and develop new antimalarial drugs preferably with novel mechanisms of 
action, multistage activity, good safety profiles and efficacy at low doses. To 
address this need, structure activity relationship (SAR) and structure property 
relationship (SPR) studies were carried out on a novel antimalarial 
chemotype, namely the pyrido[1,2-a]benzimidazoles (PBI) class of 
compounds. A frontrunner compound based on the PBI scaffold was 
previously found to possess potent antiplasmodial activity in vitro [IC50(Pf 
NF54) = 0.11 μM; IC50(Pf K1) = 0.12 μM] and promising oral efficacy (95% at 
4×50 mg/Kg p.o) in the in vivo mouse P. berghei model. However, 
pharmacokinetic (PK) studies showed oral-limited absorption attributed to 
poor dissolution or solubility. Thus a series of derivatives was synthesized by 
making structural modifications to the parent PBI scaffold by distorting the 
symmetry through introduction of small groups in the C-2 position (Figure i), in 
an effort to identify derivatives with improved solubility properties, while 
retaining antiplasmodial activity. The synthesized derivatives displayed good 
antiplasmodial activity against the chloroquine-sensitive (NF54) strain of P. 
falciparum and selected compounds against the multi-drug resistant (K1) 
strain. However, substitutions at the C-2 position resulted in derivatives with 
improved solubility at the expense of antiplasmodial activity and metabolic 
stability. In an effort to investigate the factors responsible for improvement in 
solubility, the dihedral angles of the optimized structures were derived using 
density functional theory (DFT) calculations (B3LYP/6-31G*). The calculated 
dihedral angle of compound 6.4 was compared to the experimentally 
determined dihedral angle from the single X-ray crystal structure of 6.4. A 
weak correlation (R2 = 0.4) between kinetic solubility and dihedral angle was 
observed and this suggests that there are many factors that influence 
 vii 
solubility and that dihedral angle is just one them.  
 
 
 
 
Figure i: The structures of the parent PBI compound (A) and the general PBI 
scaffold (B) representing synthesized structural derivatives. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 Malaria 
 
1.1.1 Etiology  
 
Malaria is a life threatening, mosquito-borne disease responsible for 
ubiquitous morbidity and mortality. The infectious disease is caused by five 
strains of the Plasmodium parasite. Four of these are responsible for human 
malaria namely P. falciparum, P. vivax, P. malariae and P. ovale. The female 
Anopheles mosquito functions as the malaria vector that transports the 
parasite from one person to another. Of the 400 species, only 30 species of 
Anopheles mosquito are considered important vectors.1  
 
The fifth strain of Plasmodium parasite, P. knowlesi, is known to cause 
malaria in monkeys in South-East Asia. Current research has shown that P. 
knowlesi malaria may be transferred between humans and monkeys when an 
Anopheles mosquito, infected by a monkey, bites a human.1 
 
P. falciparum is predominantly found in the African region and is responsible 
for most malaria fatalities. P. vivax is the most widespread because it can 
develop in the Anopheles mosquito vector at lower temperatures and survive 
at higher altitudes. However, it is mostly found outside of the African region 
due to many African populations who lack a protein which P. vivax requires to 
invade red blood cells.1 
 
1.1.2 Epidemiology 
 
Malaria is largely distributed in tropical areas of the world with most cases 
found in sub-Saharan Africa and the South-East Asia regions. The World 
Health Organization (WHO) reported 212 million cases of malaria in 2015, 
with 90% of these cases occurring in the WHO African region (see Table 1).  
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Table 1: A Table of the global trends in malaria incidence and mortality 
reported for 2015. 
WHO Region % Malaria cases % Malaria deaths 
Africa 90 92 
South-East Asia 7 6 
Eastern Mediterranean 2 2 
 
Young children remain exceedingly vulnerable to this disease with about 70 % 
of the 438 000 malaria deaths of 2015 occurring in children under the age of 5 
and 292 000 of these deaths were in children from the WHO African Region. 
This makes malaria the fourth highest cause of death in children with 10% of 
child deaths in sub-Saharan Africa attributed to malaria.2  
 
Amongst the 95 endemic countries and territories that continue to fight the 
ongoing battle against malaria, the global burden is heavily distributed in 
Africa where an estimated 80% of malaria cases and 78% of deaths are 
accounted for in 15 countries.2  
 
1.1.3 Life cycle and pathogenesis 
 
The Plasmodium parasite is an obligatory intracellular protozoan with 
specialized methods of traveling across tissue membranes and invading host 
cells in the mosquito vector and human host. The female Anopheles mosquito 
carries the motile forms of the parasite, known as sporozoites, in the salivary 
glands (Figure 1.1).3  
 
Upon biting the human host during a blood meal, the sporozoites are injected 
into the bloodstream (1) and travel to the liver where they invade hepatocytes 
(2).4 The asymptomatic liver stage will last for about 6 days and involves 
sporozoites growing and dividing in each hepatocyte to produce thousands of 
haploid forms known as merozoites.5 Hepatocytes rupture to release 
merozoites into the bloodstream where they invade erythrocytes and start 
asexual replication to produce new merozoites in the intraerythrocytic cycle  
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(3).6 This is known as the asexual blood stage of the infection and it is the 
pathogenic stage where the host will present clinical symptoms (4).7 During 
the asexual blood stage, parasites replicate to produce 8-20 new merozoites 
every 48 hours and thus cause parasite numbers to increase to 1013 per 
host.5 Merozoites in the infected erythrocytes will eventually leave the asexual 
multiplication stage and develop into the sexual forms that will circulate in the 
bloodstream as male and female gametocytes (5).7 The sexual stage 
parasites are nonpathogenic but are transmissible to the mosquito vector.5 
 
A mosquito that bites an infected human will ingest gametocytes with its blood 
meal (6). The gametocytes will travel to the gut of the mosquito where the 
human erythrocyte will burst to release the gametocytes (7). The gametocytes 
will develop into male and female gametes that will fuse to form diploid 
zygotes that develop into motile ookinetes that can travel to the midgut wall of 
the mosquito.8 Once they reach the midgut they form oocysts that grow and 
divide to form thousands of haploid forms known as sporozoites. After 1-2 
weeks, oocysts burst to release sporozoites that travel to the salivary glands 
of the mosquito where the infection cycle will continue.5 
 
The development of the parasite within the host brings about various 
structural, biochemical and functional changes in the erythrocytes that may 
include changes in shape, membrane rigidity and permeability to ions. These 
changes occur in response to proteins secreted by the parasite and 
interactions with erythrocyte membrane proteins. These effects allow the 
parasite to survive within the host cell for extended time periods and enhance 
the virulence of the disease which may lead to cerebral malaria and anemia.9 
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Figure 1.1. Life cycle of the Plasmodium parasite.6  
 
1.1.4 Chemotherapy and treatment challenges 
 
Cost-effective interventions can lead to the treatment and control of malaria. 
Such measures involve case management for early detection and prompt 
diagnosis, vector control that aims to reduce the transmission of the disease 
between parasite and human and chemoprevention to suppress the infection 
in humans.1  
 
One of the first agents used for the treatment of malaria was the bark of the 
Cinchona tree. The structure of one of the active components in the bark, 
quinine (1), was elucidated in 1908.10 Due to the side effects associated with 
the toxicity of quinine such as diarrhea, nausea, stomach cramps and 
vomiting, as well as its requirement for multiple dosages, structure-activity 
relationship (SAR) studies led to the development of the successful derivative 
chloroquine (2).11 Chloroquine was first synthesized in 1934 and became the 
most common first-line treatment for a variety of parasites due to its low cost, 
high efficacy and easy accessibility.12 The first case of chloroquine-resistant 
P. falciparum was reported in 1961 in Colombia.13 Chloroquine-resistance 
escalated dramatically and led to the development of the structurally related, 
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quinoline-based synthetic derivatives that include mefloquine (3) and 
halofantrine (4), as seen in Figure 1.2.14   
 
These compounds are highly active against chloroquine-resistant strains 
albeit parasite-resistance to these drugs has developed rapidly. Furthermore, 
these drugs are known to cause unfavorable side effects. Halofantrine is 
known to cause diarrhea, vomiting and headaches and mefloquine may cause 
dizziness, anxiety, hallucinations and depression.15,16 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Structures of quinoline-based antimalarial drugs.  
 
Artemisinins have been identified as non-quinoline-based antimalarial drugs. 
The parent drug, artemisinin (5), is derived from the sweet wormwood 
Artemisia annua. The antimalarial properties of this sesquiterpene lactone 
were discovered in the 1970s by Chinese scientists. It is the fastest acting 
drug against P. falciparum. However, the short half-lives and rapid clearance 
of artemisinin and its semi-synthetic derivatives is a drawback to effective 
deployment.17  
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Although their mode of action is still not well understood, artemisinins are 
unique in the fact that they target the asexual parasites of the blood stage 
infection and cause rapid clearance. In addition, these drugs target 
gametocytes, which are responsible for transmission.18 By the 1990s, 
artemisinin monotherapies were widely used in Asia. In 2001, the WHO 
recommended replacement of artemisinin monotherapies with artemisinin 
combination therapies (ACTs) to stop the spread of drug-resistant strains.19 
 
In ACT treatment, the artemisinin derivative (6) is paired with a long acting 
partner drug that has a different mechanism of action. The purpose of 
combination therapy is to minimize opportunities for drug resistance to 
develop and spread.18 By 2012, 99% of ACT deliveries consisted of fixed-
dose combination ACTs, which consist of two active drugs combined into a 
single tablet. This type of delivery allows for improved patient adherence.20  
 
The first ACT, artemether-lumefantrine (Figure 1.3), was registered in 1992 
and administered as a single tablet.17 By 2010, 56 countries were using 
artemether-lumefantrine as a first- or second-line treatment. There are five 
combinations of ACTs that are currently recommended to treat malaria 
namely: artemether-lumefantrine, artesunate-amodiaquine, artesunate-
mefloquine, artesunate-sulfadoxine-pyrimethamine and dihydroartemisinin-
piperaquine. The choice of treatment is dependent on the therapeutic efficacy 
of the combination therapy in a particular region.21  
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Figure 1.3. Structures of artemisinin (5), artemisinin derivatives (6) and the 
partner drug, Lumefantrine (7).  
 
Resistance to artemisinins has been reported in Cambodia, Thailand, 
Vietnam, Myanmar and the Lao People’s Democratic Republic.22 Until now, 
the partner drug in the combination therapy has ensured that patients still 
respond effectively to ACT treatment. Thus resistance to the partner drug will 
have serious consequences for ACT treatment regimens.1 
 
Atovaquone (8) is an antimalarial agent that inhibits mitochondrial electron 
transport in the parasite. Despite its excellent efficacy, the rapid development 
of parasite resistance means it is typically used in prophylaxis in a synergistic 
combination with proguanil (9) (Figure 1.4). This fixed-dose combination 
therapy has fewer side effects but comes at a high cost.23  
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Figure 1.4. Structures of atovaquone (8) and proguanil (9).  
 
Tetracycline (10) and lincomycin (11) are antibiotics that have played an 
important role in the development of antimalarial drugs (Figure 1.5). 
Doxycycline (12) is a synthetically derived tetracycline used as a prophylactic 
drug for travellers. It can be used to treat malaria when used in conjunction 
with a fast acting schizontocidal agent. Quinine can be used with doxycycline 
to treat chloroquine-resistant malaria caused by P. falciparum and P. vivax. 
This combination therapy is especially successful to treat the disease in areas 
where chloroquine- and multidrug-resistant malaria limits treatment options.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Structures of antibiotics used as antimalarial drugs.24 
 
The advantage of antibiotics is that the safety concerns regarding pregnant 
women is known and thus they can be used to treat pregnant women in their 
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first trimester of pregnancy. However, there are concerns regarding the 
development of resistant strains.25  
 
The high cost, toxicity and rising emergence of resistant strains of the 
Plasmodium parasite are limiting the use of the available and potential 
antimalarial treatments. Due to the fact that there are few alternatives to 
ACTs, there is an urgent need for new antimalarial drugs with novel 
mechanisms of action as well as better safety and resistance profiles.  
 
 
1.2 Strategies in Antimalarial Drug Discovery 
 
1.2.1 Introduction 
 
A combination of scientific and technological advancements has transformed 
drug discovery over the past 100 years. Early drug discovery approaches 
were focused on observing the phenotypes that substances induced in 
humans and animals. The rise of the technological age in the late 1990s saw 
major advancements in the knowledge of how drugs produce a phenotype 
and led to the emergence of the target-based screening approach. This 
section focuses on the efficiencies of these major strategies, as well as 
targeting the host hemoglobin degradation as a valuable tool in antimalarial 
drug discovery. 
 
1.2.2 Target-based screening 
 
Target-based screening is a strategy that investigates the chemical response 
induced by a compound when it acts on a particular biological target.26 With 
the advancement of biochemistry and the pioneering of genomics in the 
1980’s, target-based screening started generating interest as it began 
replacing the standard approach of phenotypic screening.27 
 
This approach received increased attention as structural biology and 
computational tools developed that allowed for more structure-based drug 
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discovery.  This technology meant that compounds could be designed to 
specifically bind to a particular target and therefore provide more information 
regarding the mechanism of action of the drug, which phenotypic screening 
lacked at the time.28  
 
However, compounds identified through this approach have occasionally 
displayed inactivity against the whole cell or in whole organism assays.29 
Recent years have seen a decline in the use of target-based approaches as 
researchers have concluded that it may limit the breadth of new findings.27  
 
1.2.3 Phenotypic whole-cell screening 
 
Phenotypic screening is an approach that involves the successive testing of 
compounds in a biological system (e.g. cells, tissues, whole organisms) to 
induce a desired effect or phenotype.26 Despite many opinions regarding 
which approach is superior, between target-based and phenotypic whole-cell 
screening, the contribution of first-in-class small molecule drugs developed 
between 1999 and 2008 by phenotypic screening surpassed the amount by 
the target-based approach. 30  
 
The advantage of phenotypic screening is the potential of identifying 
biologically active compounds that act on a novel target or simultaneously act 
on more than one target and thus reduce the likelihood of resistance. This 
approach has the additional advantage of producing hits with important drug-
like properties (e.g. cell penetration) as it takes into account the real biological 
environment in which compounds will have to interact with targets.27,31 
Furthermore, phenotypic screening provides the advantage of discovering 
new disease biology in the cases where it is not well understood.32 
 
The well-known challenges of phenotypic screening that has rendered it “the 
road less travelled” to many drug discovery teams are the difficulties 
accompanied with identifying the relevant target(s) of the drugs and 
understanding the mechanism of action.33 The resurgence of phenotypic 
screening over the last few years is as a result of new technologies in 
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chemogenetics and chemical proteomics that have been developed to 
advance target identification techniques.34–36 A review by Guiguemende et 
al.37 reports on how phenotypic whole cell screening has played a key role in 
the malaria drug discovery programs over the last few years.37 
 
1.2.4 Hemoglobin degradation 
 
When the malaria parasite enters the host bloodstream, it invades the 
erythrocytes. It then ingests the hemoglobin (Hb) from the erythrocyte through 
a process known as pinocytosis (Figure 1.6).38 Once the Hb enters the food 
vacuole (FV) of the parasite, it is digested by protease enzymes resulting in 
the release of small peptides, which are a nutrient source for the parasite.39 
Simultaneously, free heme [Fe(II)PPX] is released and is subsequently 
oxidized to  hematin (ferriprotoporphyrin IX, [Fe(III)PPX]), known to be toxic to 
the parasite. To overcome this hematin toxicity, the parasite uses an inherent 
heme detoxification system. This system allows the parasite to convert toxic 
hematin [Fe(III)PPX] to a non-toxic crystalline form known as hemozoin.40  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The pathway of hemozoin formation.40 
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Antimalarial drugs, such as chloroquine, are known to act through inhibition of 
the formation of the non-toxic hemozoin by forming π-π complexes with 
heme. This results in the accumulation of toxic heme in the food vacuole of 
the parasite, which leads to parasite death.41  
 
The availability of assays based on β-hematin, the synthetic equivalent of 
hemozoin, has facilitated screening for inhibition of β-hematin formation. The 
strategy for the rational drug design of novel antimalarial β-hematin inhibitors 
(BHI) requires compounds that form strong complexes with heme and thus 
inhibit the formation of β-hematin. In addition, compounds need to accumulate 
in the food vacuole of the parasite.42  
 
 
1.3 Solubility 
 
1.3.1 Introduction 
 
Solubility is a physicochemical property that describes the ability of a 
compound to dissolve in a solvent at equilibrium. It has a major impact on the 
bioavailability of a drug. Early stage solubility information is essential for 
analyzing SAR studies of lead compounds to allow for structure-solubility 
relationships to be explored.43 
 
Early on in the drug discovery and development (DDD) process, solubility may 
be used as a parameter to determine whether a class of compounds is viable 
for SAR studies in the hit-to-lead stage. In the lead optimization stage, 
solubility becomes a major issue because molecular modifications made to 
improve target-protein binding may become detrimental to the 
physicochemical properties of the molecule such as solubility.44  
 
Since poor solubility may lead to assay inaccuracies and developmental 
challenges, a more holistic approach is favorable as the focus is then divided 
between activity and drug-like properties. This approach yields better drug 
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candidates because a less potent drug may have improved drug-like 
properties that translate to superior in vivo results.43  
 
1.3.2 Strategies to improve solubility  
 
Structural properties determine the in vivo physicochemical and biochemical 
properties, pharmacokinetics and toxicity of a drug.43 Various strategies can 
be employed to improve solubility. Structural modification strategies include 
the addition of ionizable groups, polar groups, hydrogen bonding, reducing 
molecular weight, reducing logP, disruption of molecular planarity and 
symmetry or constructing a pro-drug. However, these strategies may not 
always have the desired outcomes.  
 
The common approach of introducing hydrophilic groups to improve aqueous 
solubility may result in decreased target protein-drug interactions. This is the 
case when the newly introduced hydrophilic groups form new hydrogen bonds 
that induce tighter crystal packing. In addition, the aforementioned strategy 
may not be viable in the case where solubility and hydrophobicity need to be 
improved.45  
 
The aqueous solubility of a solid solute depends on the crystal packing of the 
solute as well as the ability of the solute to interact with water.46 Therefore, 
disruption of the crystal packing could be considered as a unique alternative 
to improve aqueous solubility. Due to the fact that molecular planarity and 
symmetry affect crystal packing, it can be hypothesized that disruption of 
molecular planarity would result in less efficient crystal packing which may 
lead to decreased melting point and improved solubility of the compound.45 
 
Ishikawa et al.45 published work that focused on improving aqueous solubility 
by disrupting molecular planarity and symmetry through various chemical 
modifications. These modifications included removal of aromaticity, 
introduction of substituents into benzylic positions, twisting of fused rings and 
increasing dihedral angles. Disrupting molecular planarity by introducing small 
hydrophobic substituents in ortho positions of aromatic rings increases the 
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dihedral angle and lowers the crystal packing energy. This results in a 
decreased melting point and an increase in solubility.45 
 
Melting point, dihedral angles and retention time on reverse-phase HPLC 
were used to examine any changes in physicochemical properties. Fluorine 
was reported to be an optimal substituent to disrupt molecular planarity and 
improve aqueous solubility owing to its small Van der Waals radius, next to 
hydrogen. Therefore, it is expected to have the least impact on target protein-
drug interactions. This approach also allows for aqueous solubility to improve 
without increasing the molecular size, which may have unfavorable 
pharmacokinetic consequences.45 
 
1.4 Drug Metabolism  
 
1.4.1 Introduction 
 
Drug metabolism is the process whereby a xenobiotic is chemically modified 
by enzymes to clear the compound from the body. The purpose of this 
biotransformation process is to increase the clearance of the drug and reduce 
exposure, which results in low bioavailability. Metabolism of all xenobiotics 
occurs mainly in the liver and other major organs such as the kidneys, lungs, 
skin and blood-brain barrier.43,47  
 
Metabolism is divided into three phases. Phase I metabolism involves 
structural modifications, mainly catalyzed by cytochrome P450 (CYP) 
enzymes through oxidation, reduction and dealkylation. Phase II metabolism 
results in the conjugation of phase I metabolites with other hydrophilic 
molecules, which ultimately increase the aqueous solubility of these products 
in order to promote excretion from the body via bile and urine.48,49 Phase III 
metabolism consists of drug transporters located in the epithelial and 
endothelial cells of the liver, gastrointestinal tract, kidney and blood-brain 
barrier. They transport drugs across cellular membranes and are thus 
responsible for the concentrations of the drug at the target site.50  
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1.4.2 Metabolic stability of drug candidates 
 
Metabolic stability is a vital property in drug discovery that directly affects the  
pharmacokinetics (PK) of a drug. Quantitative metabolic stability studies are 
used to prioritize compounds for in vivo studies by evaluating the extent of 
metabolic breakdown. Qualitative metabolite structure studies are used to 
determine metabolic soft spots in order to design structural modifications that 
may sterically hinder the site of metabolism in an effort to improve the stability 
of the compound.43  
 
In vitro models have been developed to allow the study of drug metabolism 
and metabolite identification during the drug discovery and development 
process. Since the liver is the predominant organ for metabolism, several in 
vitro human liver models have been developed in an effort to resemble 
metabolism in vivo in the liver. These in vitro human liver models are 
designed to reduce complexity of the study system.51 
 
Pooled liver microsomes, liver S-9 fractions and hepatocytes are the three 
most commonly used in vitro models in the lead optimization and 
development process.52 Liver microsomes are the most frequently used in 
vitro models. Though they don’t possess as many metabolizing enzymes as 
hepatocytes, they include the important cytochrome P450 enzymes which are 
involved in the metabolism of 60 – 80 % of marketed drugs.51  
 
Different animal liver microsomes are used to determine the best in vivo 
model for further testing. The transgenic mouse is a common efficacy model 
used to determine dosing concentrations for proof-of-concept studies. The rat 
is used for safety studies while in vitro work in the human model is used to 
make predictions for clinical studies.43,51 
 
Drug optimization needs to be carried out with pharmacological activity, safety 
and metabolic stability in mind in order to ensure more efficient and 
successful drug discovery and development projects.53  
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CHAPTER 2: SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF 
SIDE-CHAIN MODIFIED PYRIDO[1,2-a]BENZIMIDAZOLES 
 
2.1 Introduction 
 
This chapter describes the synthesis of pyrido[1,2-a]benzimidazole (PBI) 
derivatives obtained by performing SAR studies around a previously identified 
parent compound. These derivatives are aimed at improving antiplasmodial 
activity and solubility. The synthesized compounds were evaluated for 
solubility and in vitro antiplasmodial activity against the chloroquine-sensitive 
(NF54) strain, and selected compounds against the multidrug resistant (K1) 
strain, of Plasmodium falciparum. Towards elucidating the mechanism of 
action, compounds were also tested for β-hematin inhibition activity. Factors 
affecting solubility were also investigated.  
 
2.2 Background 
 
PBIs are compounds made up of a tricyclic nucleus. Their heterocyclic 
framework consists of a pyridine ring fused to a benzimidazole moiety (Figure 
2.1). In naming this system, the benzimidazole moiety takes precedence as 
the base because it is made up of more rings than the pyridine ring. The 3 
characters in the square bracket are the locants and they indicate which bond 
is common to both rings. The first 2 numbers in the square brackets (i.e. 1,2) 
refer to the numbers in the pyridine ring and the third character is an 
alphabetical character which refers to the bond as viewed from the 
benzimidazole ring. The numbering is assigned such that the lowest numerals 
and alphabet characters are chosen.54 
 
 
 
 
 
Figure 2.1: The general structure of pyrido[1,2-a]benzimidazoles.  
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2.2.1 Biological activity of pyrido[1,2-a]benzimidazoles 
 
The numerous biological activities of, and diverse synthetic routes to, PBI 
compounds have attracted interest from medicinal chemists in recent years. 
The biological activities range from anticancer55 (13), antifungal (14)56, 
antimycobacterial (15)57, antiviral58 (16), anxiolytic59 (17) and antiparasitic60 
(18). In addition, mechanistically they have shown potential as DNA 
intercalators61 and perforin inhibitors62 (Figure 2.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Structures of biologically active PBIs. 
 
2.2.2 Pyrido[1,2-a]benzimidazoles as antimalarial agents 
 
In 2011, Ndakala et al.63 reported, for the first time, the antimalarial activity of 
PBIs. A small library of diverse compounds had previously been screened in 
vitro against a group of protozoa and the moderate antiplasmodial activity of 
PBIs was identified (Figure 2.3). 
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Figure 2.3: The PBI scaffold used for SAR exploration by Ndakala et al.63 
 
Further SAR studies led to the identification of a more potent PBI derivative 
(19 with IC50 values of 0.11 μM and 0.047 μM against NF54 and K1 strains, 
respectively.  Compound 19 also showed significant efficacy in Plasmodium 
berghei infected mice following both intraperitoneal (ip) and oral (po) 
administration, with >90% inhibition of parasitemia (4 x 25 mg/kg). However, 
in vitro metabolic stability studies showed that 19 has a high rate of metabolic 
degradation and compound 20 was identified as its major metabolite, formed 
through N-dealkylation (Figure 2.4), with antiplasmodial activity comparable to 
19. However, in vivo (mouse) pharmacokinetic studies of compound 20 
indicated that the oral absorption becomes saturated at relatively low doses, 
most likely because of poor dissolution or solubility.63  
 
 
 
 
 
 
 
Figure 2.4: The structure of the lead compound (19) as well as the metabolite 
(20) identified during SAR studies. 
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2.3 Rationale 
 
As indicated above, in vivo pharmacokinetics studies revealed an apparent 
solubility-limited absorption of compound 20. Therefore, the main focus of this 
study was to improve the solubility of 20 while also expanding SAR studies on 
parts around the PBI core not previously explored. 
 
As mentioned in Chapter 1, various approaches can be used to improve 
solubility.  The main approach used in this study involves disrupting the 
molecular planarity and/or symmetry of the molecule by introducing small 
hydrophobic substituents, such as a methyl or fluorine group, in appropriate 
positions of the PBI core. Thus in order to further explore SAR studies, 
various substituents were introduced at various positions around the core. 
 
2.4 Research Question 
 
The research question is whether it will be possible to identify novel PBI-
based antimalarial drug leads with favorable solubility, whilst retaining and/or 
improving desirable pharmacological properties. 
 
2.5 Objective 
 
The objective of this study was to optimize side-chain modified antimalarial 
PBIs with respect to solubility, metabolic stability and antiplasmodial activity. 
An attendant objective was mechanistic evaluation of compounds with respect 
to inhibition of β-hematin formation. 
 
2.6 Specific Aims 
 
i. Synthesis of PBI target compounds. 
ii. Characterization of target compounds using spectroscopic and 
analytical techniques. 
iii. In vitro profiling with respect to antiplasmodial activity, cytotoxicity, 
solubility, metabolic stability and β-hematin inhibition. 
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iv. Determination and evaluation of factors that may be responsible for 
improved solubility and deduce relationships.  
 
2.7 Synthesis and Characterization 
 
2.7.1 Introduction  
 
Initial SAR studies were designed to determine the effect of incorporating 
small and large hydrophobic groups at C-2 (Figure 2.5) as this was postulated 
to be the optimal position for disruption of planarity in an effort to improve 
solubility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: PBI scaffold used for SAR exploration. 
 
The amine side-chains were selected based on their potential to improve 
solubility. The 2-aminoethyl-3-pyrrolidinol moiety can act as a hydrogen bond 
donor and acceptor, and as such has potential to improve solubility. The 
Mannich base side-chain is a well-known moiety found in antimalarial drugs 
such as amodiaquine, amopyroquine and tebuquine (Figure 2.6). This side-
chain is able to form an intramolecular hydrogen bond network that is 
expected to benefit solubility. 
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Figure 2.6: Structures of (21) amodiaquine, (22) amopyroquine and (23) 
tebuquine with Mannich base side-chains. 
 
Unlike large hydrophobic substituents such as methyl and benzylic groups, 
fluorine has the smallest Van der Waals radius next to hydrogen and is less 
likely to interfere with protein-drug interactions due to its small size. Thus, a 
fluorine atom is more likely to increase the dihedral angle without loss of 
biological activity.45  
 
A recent publication by our group revealed that appropriate modifications on 
the benzimidazole moiety of the PBI core (X in Figure 2.5) improved the in 
vitro antiplasmodial activity and metabolic stability.64 Substitutions were made 
at this position, whilst simultaneously incorporating substitutions at C-2.  
 
2.7.2 Synthesis of target pyrido[1,2-a]benzimidazoles  
 
The retrosynthetic analysis of the PBI target compounds is outlined in 
Scheme 1.  
 
The target compounds (viii) were synthesized through a nucleophilic 
substitution reaction of the chlorinated intermediates with the appropriate 
amine. The chlorinated intermediates (vii) were synthesized by reacting the 
hydroxyl intermediates with phosphorus oxychloride (POCl3) in a dehydration 
reaction. 
 
A condensation reaction between the benzimidazole intermediates (iv) and 
the respective β-keto esters (v) afforded the hydroxy intermediates (vi).63 
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Substituted benzimidazole intermediates (iv) were synthesized in a 
condensation reaction between ethyl-2-cyanoacetate (i) and the appropriate 
diamine (ii). The substituted β-keto esters (v) were synthesized from iii using 
literature methods.57,65 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Retrosynthetic analysis of PBI target compounds. 
 
The reaction scheme for the synthesis of the PBI target compounds can be 
seen in Schemes 2. Target compounds were obtained in low to moderate 
yields (Table 2). 
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Scheme 2: General synthetic approach for the synthesis of target compounds, 6.1 – 6.15. 
Reagents and conditions: (a) MeI, K2CO3, MeCN, 50°C, 2 h; (b) Selectfluor, MeCN, 
microwave (150 W), 82°C, 10 min;  (c) appropriate benzyl halide, tBuOK, tBuOH, THF, 70°C, 
8 - 24 h, (d) DMF, 150°C, 2 h; (e) NH4OAc, 145°C, 1 h; (f) POCl3, 130°C, 2 - 8 h; (g) 
appropriate amine, THF, Et3N, microwave (150 W), 80°C, 20 – 40 min. 
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Table 2: Target Compounds with Isolated Yields 
 
 
 
 
 
 
 
The synthesis of 6.6 (LB76) is used as an illustrative example to explain 
reaction mechanisms and compound characterisation.  
 
 
Compound X R1 R2 R Yield (%) 
Expected  
mass 
m/z 
Observed 
mass  
m/z 
6.1 (LB 10) H CH3  4-CF3Ph 65 437.2 438.2 [M+1]+ 
6.2 (LB 20) H F  4-CF3Ph 19 441.2 442.1  [M+1]+ 
6.3 (LB 29) H CH3  4-CF3Ph 56 479.2 480.2 [M+1]+ 
6.4 (LB 34) H F  4-CF3Ph 44 483.2 484.2 [M+1]+ 
6.5 (LB 27) H H  4-CF3Ph 32 465.2 466.2 [M+1]+ 
6.6 (LB 97) H F  4-CF3Ph 11 547.2 548.1 [M+1]+ 
6.7 (LB 76) 7,8-Cl F  4-CF3Ph 28 509.1 510.1 [M+1]+ 
6.8 (LB 75) 7,8-Cl H  4-CF3Ph 24 491.1 492.1 [M+1]+ 
6.9 (LB 94) 7,8-F F  4-CF3Ph 5 477.1 478.1 [M+H]+ 
6.10 (LB 85) 7,8-F H  4-CF3Ph 71 459.2 460.2 [M+1]+ 
6.11 (LB 88) 7,8-F H 
 
4-CF3Ph 26 565.2 566.2 [M+1]+ 
6.12 (LB 45) H   CH3 7 383.5 384.2 [M+1]+ 
6.13 (LB 49) H   CH3 20 417.2 418.1 [M+1]+ 
6.14 (LB 53) H   CH3 31 417.2 418.1 [M+1]+ 
6.15 (LB 59) H   CH3 20 417.2 418.1 [M+1]+ 
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2.7.2.1 Synthesis of benzimidazole intermediates 
 
For the synthesis of the benzimidazole moiety substituted compounds, the 
initial step in the synthetic route involves a condensation reaction to afford the 
substituted benzimidazole.  
 
The reaction mechanism for the formation of intermediate 3.2, involves attack 
by the lone pair electrons of the nitrogen of the dichloro diamine phenyl (a) on 
the carbonyl carbon of ethyl cyanoacetate, followed by a proton transfer and 
the subsequent loss of ethanol (b) to yield intermediate c (Scheme 3). The 
lone pair of electrons on the other nitrogen atom of c attacks the carbonyl 
carbon, which leads to the formation of the 5-membered ring intermediate (d). 
A second proton transfer generates a hemi-aminal (e) and subsequent loss of 
a water molecule from intermediate f affords the benzimidazole intermediate g 
(3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3: Synthetic route for the synthesis of the benzimidazole 
intermediates. 
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Spectroscopic analysis of the benzimidazole intermediate 3.2 
 
The 1H NMR (400 MHz, DMSO) spectrum of 3.2 confirmed the presence of 
signals in the region of δ 12.0 – 13.0 corresponding to NH, two aromatic 
protons and the two aliphatic protons of the acetonitrile moiety (Figure 2.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: 1H NMR (400 MHz, DMSO-d6) spectrum of the benzimidazole 
intermediate, 3.2.	
 
2.7.2.2 Synthesis of the hydroxy intermediate 4.4 
 
In the condensation reaction to form the hydroxy intermediate 4.4, ammonium 
acetate deprotonates the carbon of acetonitrile 3.2 to form a carbanion (i), as 
seen in Scheme 4. This carbanion attacks the electrophilic carbonyl carbon of 
the substituted β-keto ester. Intramolecular cyclization (k-o) followed by the 
loss of water and ethanol results in the intermediate, p (4.4). 
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Scheme 4: Synthetic route for the synthesis of the hydroxy intermediate, 4.4. 
 
Spectroscopic analysis of the hydroxy intermediate 4.4. 
 
The structure of the hydroxy intermediate was confirmed by 1H NMR (400 
MHz, DMSO-d6), as seen in Figure 2.8. The spectrum of 4.4 shows the 
presence of 6 aromatic signals in the region δ 7.7 – 8.7. The distinctive 
splitting pattern of the four protons of the para-substituted benzene ring is 
seen as the pair of doublets (J = 7.8 Hz) that arises due to the symmetry of 
this moiety. 
 
According to Ndakala et al.63, the 13C spectrum of this intermediate 
corresponds to the enol tautomer with a signal at δ 157.9 for C-1. However, 
other groups have published it as the keto tautomer (Figure 2.9) with a 13C 
signal in the region of δ 158-159, along with a 1H signal corresponding to the 
NH at δ 13.46.66 Since the 1H spectra of the PBI intermediates in this project 
display no signals that correspond to a NH, we have chosen to represent 
these intermediates as the enol tautomer. 
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Figure 2.8: 1H NMR (400 MHz, DMSO-d6) spectrum of the hydroxy 
intermediate, 4.4. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Keto (i) and enol (ii) tautomer of 4.1  
 
 
2.7.2.3 Synthesis of the C-1 chlorinated intermediate 5.4 
 
The hydroxy intermediate 4.4 was reacted with phosphorus oxychloride 
(POCl3) to afford the chlorinated intermediate 5.4 (Scheme 5). 
Mechanistically, the lone pair of electrons of the hydroxyl oxygen attacks the 
electrophilic phosphorus of POCl3 (q) and the subsequent electron transfer 
results in the loss of a chloride ion (r). The electron deficiency of the oxygen 
enhances the electrophilicity of the electrophilic carbon and the chloride ion 
attacks the electrophilic carbon of this phosphorous intermediate (s). The 
subsequent loss of HCl and PO2Cl results in the formation of the chlorinated 
intermediate, 5. 
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Scheme 5: Synthetic route for the synthesis of the C-1 chlorinated 
intermediate, 5.4. 
 
Spectroscopic analysis of the chlorinated intermediate 5.4. 
 
The 1H NMR (400 MHz, DMSO) of 5.4 confirmed the successful formation of 
the chlorinated intermediate (Figure 2.10). The 6 aromatic protons are 
observed in the region δ 7.9 – 8.3, slightly downfield from the hydroxy 
intermediate (Figure 2.8). Since the chloro group is electron-withdrawing, it 
deshields the protons more than the hydroxyl group and thus the proton 
signals shift downfield.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: 1H NMR (400 MHz, DMSO-d6) spectrum of the chlorinated 
intermediate, 5.4.		
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2.7.2.4 Synthesis of the target compound 6.7 
 
The final step in the synthetic route involves amination of the chlorinated 
intermediate, 5.4, via a nucleophilic substitution reaction to obtain the desired 
target compound 6.7, as illustrated in Scheme 6. The nucleophilic amino 
nitrogen of N-ethylethylenediamine attacks the electrophilic carbon (u). This 
causes electrons from the pyridine ring to move in such a way that a negative 
charge resides on the nitrile nitrogen due to the extended conjugation. As 
electrons move back into the pyridine ring through the resonance effect, the 
chloride ion, being a good leaving group, is displaced in a nucleophilic 
aromatic substitution reaction (v). Triethylamine mops up the liberated HCl 
produced alongside the target compound (6.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6: Synthetic route for the synthesis of the target compound, 6.7.	
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Spectroscopic analysis of selected target compounds. 
 
The structure of the target compound (6.7) was confirmed using 1D and 2D 
NMR spectroscopy (Figure 2.11). The diagnostic feature of the 1H NMR 
spectrum of 6.7 is the appearance of the aliphatic proton signals of the 
alkylamine side-chain in the region δ 1.2 – 4.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: 1H NMR (400 MHz, DMSO-d6) spectrum of the target compound, 
6.7. 
 
In the case of target compound 6.11; the protons of the benzene ring of the 
Mannich base were assigned using the relative coupling constants (Figure 
2.12). The ortho coupling observed between H21 and H22 gives rise to a 
coupling constant of 3JHH-o = 8.5 Hz for the doublet assigned to H21. The meta 
coupling between H18 and H22 results in a coupling constant of 4JHH-m = 2.6 Hz 
for the doublet of H18. Due to H22 coupling with two non-equivalent neighbors, 
H18 and H21, the signal appears as a doublet of doublets. 
 
As seen in Figure 2.12, the signals for the two protons on the fluorine 
substituted benzimidazole moiety, H6 and H9, each appear as a doublet of 
doublets compared to one doublet for the same protons on the 7,8-dichloro 
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substituted target compound, 6.7, above (Figure 2.11). This is attributed to the 
spin active nature of 19F, which has a nuclear spin of !" that allows for ortho 
coupling  (3JHF-o = 11.5 Hz) between H9 and the vicinal fluorine on C-8 as well 
as meta coupling (4JHF-m = 8.7 Hz) to the fluorine of C-7. A similar trend is 
observed for H6. These two protons, being in chemically similar environments, 
were assigned based on the through space effects from the NH to H9. The H9 
is deshielded by hydrogen bonding with the NH nearby. 
 
Furthermore, the protons of the alkylamine moiety of the Mannich base 
appear as one quartet and one triplet signal owing to the symmetry of this 
region. Therefore, H24 and H26 are in a similar chemical environment and the 
same is true for H25 and H27. The singlet at δ 4.08 corresponds to the 
methylene linker and the singlet at δ 5.59 corresponds to the aromatic proton 
on C-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: 1H NMR (400 MHz, DMSO-d6) spectrum of the target compound, 
6.11.  
 
The pyrrolidinol target compounds (6.3 – 6.5) were obtained as a racemic 
mixture as expected. The pyrrolidinol side chain has a stereogenic centre at 
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C-20. As seen in the 1H NMR spectrum of 6.4 in Figure 2.13, the signal of the 
stereogenic proton (H20) appears as a multiplet in the region of δ 4.25 – 4.35 
due to its diastereotopic nature. The signals for the other protons of the 
pyrrolidinol ring seem to be affected by the diastereotopicity because they do 
not show defined splitting patterns but are instead observed as multiplets. 
Further structure confirmation is provided by the crystal structure of 6.4 in 
which the oxygen atom of the hydroxyl group was disordered over two 
positions (see 2.9.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: 1H NMR (400 MHz, DMSO-d6) spectrum of the target compound, 
6.4. 
 
The protons of the para-substituted phenyl ring were assigned based on the 
substitution of the electron withdrawing trifluoromethyl group. This group 
removes electron density at the ortho- and para-positions and thus these sites 
are more deshielded. On this basis, H13 and H15 are more deshielded than H12 
and H16. 
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2.8 Pharmacological Evaluation and Physicochemical Properties 
 
2.8.1 Antiplasmodial, β-hematin and cytotoxicity evaluation 
 
The synthesized target compounds were evaluated for in vitro antiplasmodial 
activity against the chloroquine-sensitive (NF54) strain of P. falciparum and 
for cytotoxicity against the Chinese Hamster Ovary (CHO) mammalian cell 
line. The IC50 values obtained are displayed in Table 3. 
 
Due to their flat heterocyclic nature like that of chloroquine, it was 
hypothesized that PBIs could act by inhibiting the formation of hemozoin. 
Therefore, compounds were tested in the β-hematin inhibition assay (BHIA) 
which is used to determine whether a compound is able to inhibit the 
formation of β-hematin and to quantify the β-hematin inhibition (Table 3). A 
compound with a BHIA IC50 value below 100 µM is considered to be a β-
hematin inhibitor.67  
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Table 3: In Vitro Antiplasmodial Activity, Cytotoxicity and BHIA 
Evaluation of Pyrido[1,2-a] benzimidazole Derivatives 
 
 
 
 
Compound X R1 R2 R 
Antiplas-
modial 
Activity 
(NF54) 
IC50 (µM) 
Antiplas-
modial 
Activity 
(K1) 
IC50 (µM) 
Cyto-
toxicity 
(CHO) 
IC50 (µM) 
SI 
BHIA 
IC50 
(µM) SD 
Chloroquine     0.021 0.194   16.52 1.04 
Emetine       0.095(±0.002)    
Amodia-
quine 
        16.25 4.37 
Pyrimeth-
amine 
        NIa NIa 
20 H H 
 4-CF3Ph 0.12 NDb 1.56 (±0.03) 13 40.5 0.59 
6.1 (LB 10) H CH3 
 
4-CF3Ph 1.28 NDb 8.3 (±3.7) 6.5 200.6 25.73 
6.2 (LB 20) H F 
 
4-CF3Ph 5.53 NDb >227  41 245.4 61.51 
6.3 (LB 29) H CH3 
 
4-CF3Ph 0.55 NDb 25 (±3.8) 45.5 269.0 42.74 
6.4 (LB 34) H F 
 
4-CF3Ph 0.19 NDb 
>207 
(NDb) >1000 106.4 31.88 
6.5 (LB 27) H H 
 
4-CF3Ph 0.04 NDb 
6.12 
(±1.2) 153 85.3 2.5 
6.6 (LB97) H F 
 
4-CF3Ph 0.35 NDb 
>100 
(NDb) >288 12.2 1.27 
6.7 (LB 76) 7,8-Cl F 
 
4-CF3Ph 0.78 0.92 7.40 (0.5) 9.4 30.8 NDb 
6.8 (LB 75) 7,8-Cl H 
 
4-CF3Ph 0.02 NDb 
3.39 
(±0.7) 188.3 35.4 1.11 
6.9 (LB 94) 7,8-F F  4-CF3Ph 3.95 NDb 56.94 (±17.8) 
14.4 1061.4 147.34 
6.10 (LB 85) 7,8-F H 
 
4-CF3Ph 0.03 0.03 
0.43 
(±0.1) 
13.7 13.0 2.20 
6.11 (LB 88) 7,8-F H 
 
4-CF3Ph 0.07 0.07 
>100 
(NDb) 
>1538.5 9.4 2.23 
6.12 (LB 45) H 
  CH3 5.15 NDb 
75.08 
(±10.6) 14.6 1372.8 102.72 
6.13 (LB 49) H 
 
 CH3 2.18 NDb 
2.41 
(±0.9) 1.1 
987.4 67.37 
6.14 (LB 53) H 
 
 CH3 1.94 NDb 
5.98 
(±2.4) 3.1 287.3 37.78 
6.15 (LB 59) H 
 
 CH3 
 
2.36 
 
NDb NDb NDb 9269.1 875.94 
 
a NI: No inhibition 
b ND: Not determined 
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From the results in Table 3, it is evident that many of the target compounds 
showed good antiplasmodial activity against the chloroquine sensitive (NF54) 
strain of P. falciparum with activity in the sub-micromolar range.  
 
Substitution on the benzimidazole ring of the PBI core results in improvement 
of antiplasmodial activity compared to the parent compound (20), with the 
exception of 6.7 and 6.9. The most active compound, 6.8 (IC50 = 0.02 μM), 
displayed activity comparable to the antimalarial drug chloroquine (IC50 = 
0.021 μM) and was found to be 6-fold more potent than 20 (IC50 = 0.12 μM). 
Dichloro substituted compounds (6.7 [IC50 = 0.78 μM] and 6.8 [IC50 = 0.02 
μM]) displayed enhanced activity as compared to their fluorine analogous  
(6.9 [IC50 = 3.95 μM] and 6.10 [IC50 = 0.03 μM]).  
 
Substituting the N-ethylethane-diamino side-chain of 20, with 2-aminoethyl-3-
pyrrolidinol (6.5) and the Mannich base (6.11) side-chain, improved the 
activity of the lead compound by 3-fold and 1.7-fold, respectively.  
 
The three compounds with the 2-aminoethyl-3-pyrrolidinol side-chain, 6.3, 6.4 
and 6.5 (IC50: 6.3 = 0.55 μM; 6.4 = 0.19 μM; 6.5 = 0.04 μM), displayed 
improved activity compared to the corresponding N-ethylethane-diamino 
analogues 20, 6.1 and 6.2 (IC50: 20 = 0.12 μM; 6.1 = 1.28 μM; 6.2 = 5.53 μM). 
However, earlier microsomal metabolic stability studies showed that 
compounds with this side-chain were metabolically unstable in mouse liver 
microsomes and it was decided to continue investigations with compounds 
containing the N-ethylethane-diamino side-chain. 
 
The five most potent compounds are all unsubstituted at C-2. Thus, upon 
substitution at this position there is a reduction in antiplasmodial activity. 
Compound 6.4 showed the highest activity (IC50 = 0.19 μM) of the C-2 
substituted analogues (R1 = F).  
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The BHIA results in Table 3 suggest that β-hematin inhibition contributes to 
the mechanism of action of all the C-2 unsubstituted analogues. Generally the 
C-2 substituted analogues were not found to inhibit the formation of β-hematin 
with the exception of 6.7 (BHI IC50 = 30.8 μM). The two Mannich base 
analogues, 6.6 (BHI IC50 = 12.2 μM) and 6.11 (BHI IC50 = 9.4 μM), displayed 
the highest activity in the BHIA. 
 
Figure 2.14 demonstrates the linear relationship (R2 = 0.55) between in vitro 
antiplasmodial activity and BHI, with a P value of 0.0009. This relationship 
infers that all the compounds with sub-micromolar antiplasmodial activity are 
classified as β-hematin inhibitors. Thus the less potent compounds 
possessing antiplasmodial activity above 1 μM are non-β-hematin inhibitors. 
 
Generally, an R-squared value greater than 0.8 infers a strong positive 
correlation is present. Since the R-squared value of the graph in Figure 2.14 
is 0.55, it suggests that the correlation is weak and that there are other factors 
(e.g. other mechanisms or targets involved, physicochemical properties, 
accumulation, permeability in infected red blood cells etc.) that also influence 
the in vitro antiplasmodial activity, with BHI being just one of the contributing 
factors. It is noteworthy that this graph does not factor in the different in vitro 
environments of the BHIA and the antiplasmodial studies. The BHIA does not 
require the compound to cross any membranes whereas the antiplasmodial 
activity assay requires the compound to cross the membranes of infected 
erythrocytes and the parasite to reach the target in the digestive food vacuole. 
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Figure 2.14: Relationship between antiplasmodial activity and BHI of the PBI 
target compounds. 
 
The similar antiplasmodial activity against the chloroquine-resistant strain (K1) 
of the parasite on selected compounds suggests that the compounds show no 
evidence of cross-resistance since the compounds are equipotent against 
both strains. 
 
2.8.2 Microsomal metabolic stability profiling 
 
The in vitro metabolic stability of selected target compounds was assessed 
using the one point assay in mouse liver microsomes (MLM) and human liver 
microsomes (HLM) (Table 4).  
 
The stability of the compounds was classified as follows: 
• < 45 % remaining after 30 minutes = metabolically unstable 
• 45 – 90 % remaining after 30 minutes = moderately stable 
• > 90 % remaining after 30 minutes = metabolically stable
R² = 0.55364
-2 
-1.5 
-1 
-0.5 
0
0.5
1
1.5
0 1 2 3 4 5
Lo
g
[A
nt
ip
la
sm
od
ia
l (
N
F5
4)
 a
ct
iv
ity
  (
IC
50
)]
Log [BHI (IC50)]
P value = 0.0009 
 39 
Table 4: In Vitro Microsomal Stability of Pyrido[1,2-a]benzimidazole 
Derivatives in Mouse  and Human Liver Microsomes 
 
 
 
 
 
 
 
Compound X R1 R2 R 
MLM:	%	
remaining	
after	30	min 
Projected 
half- 
life (min) 
HLM:	%		
remaining	
after	30	min 
Projected 
half- 
life (min) 
Average SD	 Average SD 
Propranolol     5.7 0.4 <10 60.5 4.8 41 
Midazolam     0.1 0.1 <10 0.1 0 <10 
MMV390048     84.6 0.1 >150 93.1 3.7 >150 
20 H H  4-CF3Ph 97 9 >150 NDa NDa NDa 
6.1 (LB 10) H CH3  4-CF3Ph 80 2 100 85 4 131 
6.2 (LB 20) H F  4-CF3Ph 35 0.7 26 39 2 22 
6.3 (LB 29) H CH3  4-CF3Ph 16 2 ND
a 23 2 NDa 
6.4 (LB 34) H F  4-CF3Ph 37 3 28 ND
a NDa NDa 
6.5 (LB 27) H H  4-CF3Ph 51 1 31 13 1 ND
a 
6.7 (LB 76) 7,8-Cl F  4-CF3Ph 91 5 NDa 90 8 NDa 
6.8 (LB 75) 7,8-Cl H  4-CF3Ph 81 6 132 95 7 >150 
6.10 (LB 85) 7,8-F H  4-CF3Ph 67 10 NDa 79 7 NDa 
6.11 (LB88) 7,8-F H 
 
4-CF3Ph 30 3 ND
a 35 3 NDa 
 
a ND: Not determined 
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The C-2 unsubstituted compounds displayed moderate to high levels of 
metabolic stability, except for the Mannich base (6.11). The major metabolite 
of compound 20 resulted from terminal N-deethylation, while N-dealkylation 
and oxidation of the pyrrolidinol ring were observed as routes of metabolism 
for compound 6.5 (Figure 2.15). 
 
 
  
 
 
 
 
Figure 2.15: The metabolic soft spots (denoted in red) of the PBI analogues 
that are unsubstituted at position C-2.  
 
Most of the compounds that are substituted at the C-2 position displayed 
moderate to high rates of metabolic degradation. Substitution at this position 
appears to render the PBI core/phenyl ring vulnerable to oxidation, as seen in 
Figure 2.16, and thus dramatically lowers the metabolic stability of these 
compounds.  
 
 
 
 
 
 
 
Figure 2.16: The metabolic soft spots (denoted in red) of 6.2, which is 
substituted at position C-2, and the chemical structure of compound 6.7. 
	
Compound 6.7 (Figure 2.16) is the only C-2 substituted analogue that showed 
metabolic stability with more than 90 % remaining after 30 minutes in mouse 
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and human liver microsomes. This is presumably due to the presence of the 
two chloro-groups substituted on the benzimidazole moiety pf the PBI core. 
 
2.8.3 Solubility 
 
Kinetic and equilibrium solubility studies were carried out on all PBI target 
compounds (Table 5). These two assays differ in that the equilibrium solubility 
assay measures the amount of compound still in solution after incubation 
whereas the kinetic assay measures the amount of compound that 
precipitates out of solution.43,68 
 
Due to the short incubation time of the kinetic assay, it can be carried out in a 
high throughput fashion and is thus ideal for rapid compound assessment and 
to guide SAR studies in the hit to lead stage.68 This assay can produce 
solubility results that are higher than in the equilibrium solubility assay 
because the formation of a supersaturated solution inspires that more time is 
required for precipitation to occur.69  
 
Since equilibrium solubility does not require the compound to be made up as 
a stock solution in an organic solvent, it mimics the crystal forces of the solid 
and the mixing that takes place in the gastrointestinal tract. This assay is also 
advantageous in that it is conducted for a longer time period (24 - 72 hours) 
than the kinetic assay to allow for equilibrium to be reached. For these 
reasons the equilibrium solubility assay is favored for the lead optimization 
stage to determine whether structural modifications are improving solubility.68   
 
In kinetic solubility assays, it is generally accepted that compounds with 
solubility less than 1 µM are considered to be highly insoluble, those with 
solubility between 1 - 100 µM are moderately soluble and compounds with 
solubility greater than 100 µM are considered to be highly soluble.70 
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Equilibrium solubility is ranked as follows based on 200 µM preparations: 
• ≥ 150 µM = high 
• 5 – 150 µM = moderate 
• 5 – 49 µM = low 
• < 5 µM = very low 
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Table 5: Solubility Data for Target Compounds 
 
 
 
 
Compound X R1 R2 R 
Kinetic 
Solubility 
(µM) 
Equilibrium 
Solubility: 
PBS (pH 6.5) μM 
Reserpine 
(negative control) 
    1-5 <5 
Hydrocortisone 
(positive control) 
    >200 >200 
20 H H  4-CF3Ph 10-20 <5 
6.1 (LB 10) H CH3  4-CF3Ph 40-80 16.5 (±0.9) 
6.2 (LB 20) H F  4-CF3Ph >100 160 
6.3 (LB 29) H CH3 
 
4-CF3Ph 10-20 <5 
6.4 (LB 34) H F  4-CF3Ph 5-10 80 
6.5 (LB 27) H H  4-CF3Ph 5-10 <5 
6.6 (LB 97) H F 
 
4-CF3Ph 5-10 <5 
6.7 (LB 76) 7,8-Cl F  4-CF3Ph 40-80 23.4 (±1.2) 
6.8 (LB 75) 7,8-Cl H  4-CF3Ph 10-20 10 
6.9 (LB 94) 7,8-F F  4-CF3Ph >200 >200 
6.10 (LB 85) 7,8-F H  4-CF3Ph 10-20 <5 
6.11 (LB 88) 7,8-F H 
 
4-CF3Ph 10-20 <5 
6.12 (LB 45) H   CH3 80-160 146.5 (±2.0) 
6.13 (LB 49) H   CH3 10-20 <5 
6.14 (LB 53) H   CH3 20-40 35.6 (±4.0) 
6.15 (LB 59) H   CH3 10-20 <5 
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The results in Table 5 suggest that introducing a fluorine atom into the C-2 
position  (6.2, 6.4, 6.7 and 6.9) results in improvements in solubility compared 
to the unsubstituted analogues (20, 6.5, 6.8 and 6.10).  The most significant 
improvement in solubility is seen in the addition of fluorine to 6.10 (<5 µM) to 
give 6.9 (>200 µM), resulting in a greater than 40-fold increase in solubility. 
Compounds with Mannich base side-chains (6.6 and 6.11) showed poor 
solubility (<5 µM) in both kinetic and equilibrium solubility assays. 
 
A line graph comparing the results of the equilibrium and kinetic solubility 
assays is seen below (Figure 2.17). This graph illustrates the general 
agreement between these two methods of measuring solubility. From this 
overlay it is clear that two compounds (6.4 and 6.12) can be classified as 
moderately soluble and two other compounds (6.2 and 6.9) classify as highly 
soluble (i.e. ≥ 150 µM) in the equilibrium solubility assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: Overlay of kinetic solubility data and HPLC-based equilibrium 
solubility data. 
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2.9 Determination and Evaluation of Factors Contributing to Solubility 
 
This section investigates the possible factors that contributed towards 
solubility in the PBIs synthesized. The following factors were considered in 
this evaluation: 
 
1. Dihedral angle 
2. Single crystal XRD analysis 
3. Density Functional Theory (DFT) calculations 
4. CLogD 
5. HPLC retention time 
6. Melting point 
 
2.9.1 Dihedral angle 
 
As mentioned previously, various approaches can be used to improve 
solubility. This project focused on disrupting the molecular planarity of the 
target molecule by introducing substituents in appropriate positions of the PBI 
core. The dihedral angle is a convenient, measurable parameter that can be 
used to measure the disruption of planarity. It can be measured by X-ray 
crystal analysis or DFT calculations.45 
 
2.9.2 Single crystal XRD analysis of 6.4 
 
2.9.2.1 Introduction 
 
This section describes the single crystal X-ray diffraction analysis of 6.4 
(LB34). This compound showed good in vitro antiplasmodial activity combined 
with a good cytotoxicity profile, and was therefore selected for structural 
elucidation in an effort to provide more information regarding the effect of 
changes in the dihedral angle on solubility. 
 
Single crystals of 6.4 were grown by slow evaporation using an array of 
solvents. Acetone, ethanol and acetonitrile were the selected solvents and 
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were chosen based on their polarity. Ethanol gave rise to the appropriate 
sized crystals. The crystal structure and refinement parameters for 6.4 are 
seen in Table 6. 
 
Table 6: Crystallographic data for 6.4 obtained from ethanol 
 
 
 
 
 
 
Parameter Value 
Empirical formula 2(C25H21N5OF4).(C2H6O) 
Formula weight (g/mol) 1013.00 
Temperature (K) 173(2) 
Wavelength (Å) 0.71073 
Crystal system Monoclinic 
Space group P21 
Cell parameters (Å, °) 
a=14.8505(7)  b=9.5610(5)  c=18.1279(10) 
α=90  β=111.5666(1)  γ=90 
Cell volume (Å3) 2392.7(2) 
Crystal size (mm) 0.12 × 0.24 × 0.31 
Z 2 
Calculated density (g.cm-1) 1.405 
Θ min (°) 1.208 
Θ max (°) 28.343 
Reflections collected 21121 
Final R indices [I > 2σ(I)] 0.0618 
R indices (all data) 0.0973 
Goodness-of-fit on F2 1.011 
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2.9.2.2 General comments 
 
The structure of 6.4 crystallizes in P21 with Z = 2 (Figure 2.18). The oxygen 
atom of the hydroxyl group was disordered over two positions. The refined 
site occupancy factors were found to be 0.549 for O1A and O1B; 0.451 for 
O2A and O2B. All the fluorine atoms of the CF3 group were disordered. The 
refined site occupancy factors are 0.450 for F1A, F2A and F3A; 0.550 for 
F4A, F5A and F6A; 0.785 for F1B, F2B and F3B; 0.215 for F4B, F5B and 
F6B. The hydroxyl hydrogen on O1A, O2A, O1B, O2B and O1G could not be 
located in the different electron density maps and were excluded from the final 
structure model. The structure was refined to R factor of 0.0618.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18: The asymmetric unit (ASU) of the 6.4 solvated crystal that was 
obtained from ethanol.  
 
The ASU consists of two molecules (denoted A and B) that are hydrogen 
bonded to one ethanol molecule. The linear nitrile group at C16A (C16A-N5A) 
is coplanar to the PBI core. The structure is stabilized by various hydrogen 
bonds between the hydroxyl oxygens of pyrrolidinol and ethanol groups, and 
the nitrile nitrogen (Figure 2.19). These have donor⋯acceptor distances 
varying from 2.660 - 3.018 Å. These hydrogen bonds form chains that may be 
described as C3
3(17) in Etter’s graph system.71 Weak intermolecular C-H…F 
bonds (2.6614 – 3.1515 Å), intramolecular C-H…N bonds (2.6421 – 3.4335 Å) 
and π-π stacking are also observed.  
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Figure 2.19: The hydrogen bonding between molecules may be described as 
C3
3 (17).71 
 
2.9.3 Density Functional Theory Calculations 
 
2.9.3.1 Introduction 
 
Molecular planarity and symmetry influence the crystal packing of a molecule. 
Therefore the disruption of molecular planarity/symmetry is hypothesized to 
decrease the crystal packing energy and result in improved solubility.45 The 
structural modifications made at position C-2, as discussed in section 2.7, 
were performed in an effort to disrupt the molecular planarity of the molecule 
by increasing the dihedral angle.  
 
2.9.3.2 Calculated dihedral angles  
 
Due to the fact that only one crystal structure was obtained, density functional 
theory (DFT) calculations (B3LYP/6-31G*)72 were utilized to obtain the 
dihedral angles (Figure 2.20) of all the PBI target compounds for the 
optimized structures, as seen in Table 7.  
 
 
 
 
 
Figure 2.20:  Dihedral angles (red) measured in the PBI target compounds.
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Table 7: Calculated Dihedral Angles and Physicochemical Properties for 
PBI Target Compounds 
 
 
 
 
Compound X R1 R2   R 
Calculated 
Dihedral 
Anglesa 
(deg) 
CLogDb 
HPLC 
retention 
time (min)c 
Melting 
Point 
(°C) 
Equilibrium 
Solubility: 
PBS (pH 
6.5) μM 
20 H H 
 
4-CF3Ph 43.6 3.137 4.08 
222 - 
224 <5 
6.1 (LB 10) H CH3 
 
4-CF3Ph 82.2 3.260 3.53 
174 – 
177 16.5 (±0.9) 
6.2 (LB 20) H F 
 
4-CF3Ph 74.4 3.154 3.75 
281 - 
286 160 
6.3 (LB 29) H CH3 
 
4-CF3Ph 84.1 3.556 3.38 
236 – 
238 <5 
6.4 (LB 34) H F 
 
4-CF3Ph 75.9 3.468 3.51 
265 - 
267 80 
6.5 (LB 27) H H 
 
4-CF3Ph 66.1 3.460 3.56 
267 - 
269 <5 
6.6 (LB 97) H F 
 
4-CF3Ph 78.7 4.432 3.98 
275 - 
280 <5 
6.7 (LB 76) 7,8-Cl F 
 
4-CF3Ph 74.4 3.971 4.74 
332 - 
338 23.4 (±1.2) 
6.8 (LB 75) 7,8-Cl H 
 
4-CF3Ph 66.8 4.063 4.29 
266 - 
268 10 
6.9 (LB 94) 7,8-F F 
 
4-CF3Ph 74.8 2.932 4.14 
253 - 
260 >200 
6.10 (LB 85) 7,8-F H 
 
4-CF3Ph 66.8 2.989 3.48 
212 - 
215 <5 
6.11 (LB 88) 7,8-F H 
 
4-CF3Ph 62.1 4.229 4.15 
284 - 
288 <5 
6.12 (LB 45) H     CH3 67.8 2.389 3.22 174 – 176 146.5 (±2.0) 
6.13 (LB 49) H 
  
  CH3 67.8 3.104 3.71 
189 – 
191 <5 
6.14 (LB 53) H 
 
 
  CH3 68.0 3.093 3.60 
162 – 
166 35.6 (±4.0) 
6.15 (LB 59) H 
    CH3 59.2 3.072 3.49 200 - 202 <5 
a Calculated dihedral angle was estimated with Gaussian 09. b CLogD values were 
estimated with StarDrop, version 6.0.3. c Kinetex Core reversed-phase column (3.0 
mm x 50 mm). 
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Figure 2.21 displays an overlay of the crystal structure of 6.4 with the 
corresponding optimized structure. The dihedral angle of the crystal structure 
of 6.4 was found to be 49.0°. The calculated dihedral angle of the optimized 
structure was found to be 43.6° (Table 7). The RMSD value for the two 
superimposed structures was calculated using Mercury CSD 3.5.173 and 
found to be 0.156Å. A relatively low RMSD value such as this gives 
confidence to the calculated dihedral angles of the optimized structures. 
 
 
 
 
 
 
 
 
Figure 2.21: Overlay of the crystal structure and the optimized structure 
(black) of 6.4 obtained using DFT calculations (B3LYP/6-31G*). 
 
As seen in Table 7, most of the C-2 unsubstituted compounds (20, 6.5, 6.8, 
and 6.11) display small dihedral angles (< 67°). The C-2 substituted 
compounds show an increase in the dihedral angle relative to their 
unsubstituted analogues. 
A trend is observed between equilibrium solubility and dihedral angle (R2 = 
0.1), as seen in Figure 2.22. However, when the three outliers (6.1, 6.3 and 
6.6) were excluded, a stronger trend (R2 = 0.4) was observed. The relatively 
weak trend confirms that there are many factors that influence solubility and 
that dihedral angle is just one of them. 
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The two methyl-substituted analogues (6.1 and 6.3) may weaken the trend 
because the methyl group may be involved in weak hydrogen bonding that 
may cause tighter crystal packing. This could account for their large dihedral 
angles but low solubility.  
The third outlier, 6.6, is one of the Mannich base derivatives. Both Mannich 
bases show poor solubility that may be explained by the aromatic ring of the 
Mannich base side-chain that is available for further π- π stacking with the 
rest of the planar PBI core. However, what makes 6.6 different from the other 
Mannich base (6.11) is that it has a fluoro-group substituted at position C-2 
and thus the dihedral angle is increased relative to 6.11 (R1 = H). The weak 
trend confirms that there are many factors at play when considering solubility, 
and hydrophobicity is a contributing factor. 
 
 
 
 
 
 
 
 
Figure 2.22: Relationship between solubility and calculated dihedral angle of 
PBI target compounds. Outliers (6.1, 6.3 and 6.6) are circled in blue. 
Ishikawa et al.45 found that upon increasing the dihedral angle, the crystal 
packing energy decreased and this resulted in an increase in solubility and a 
decrease in melting point. However, from the results in Table 7, no correlation 
between melting point and solubility or dihedral angle was observed. 
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2.10 Conclusion 
 
Structural modifications were performed on the parent PBI core and 15 
analogues were synthesized. All the analogues were fully characterized using 
spectroscopic and analytical techniques such as 1H and 13C NMR 
spectroscopy, mass spectrometry, purity on reverse-phase HPLC and melting 
point. 
 
All compounds were evaluated for in vitro antiplasmodial activity, cytotoxicity 
and BHI activity. The microsomal metabolic stability of selected compounds 
was also determined. Equilibrium solubility and kinetic solubility assays were 
used to determine the effect of structural modifications on solubility. 
 
Most compounds displayed good antiplasmodial activity against the 
chloroquine sensitive (NF54) strain of P. falciparum with activity in the sub-
micromolar range. Substitutions at the C-2 position improved solubility, but 
this was at the expense of antiplasmodial activity.  
 
Compounds that are unsubstituted at the C-2 position generally showed good 
metabolic stability whereas compounds with a substituent at C-2 showed high 
levels of metabolic degradation. This position appears to make the PBI 
core/phenyl ring vulnerable to oxidation, which is largely responsible for the 
metabolic instability. 
 
DFT calculations were used to obtain optimized structures in order to 
calculate the dihedral angles of all the analogues with a view to determining 
the effect of structural modifications on the dihedral angle, and the relation to 
solubility. The optimized structure of 6.4 was compared to the experimentally 
determined crystal structure of 6.4 and these structures displayed a RMSD 
value of 0.156. The calculated dihedral angles showed a moderate correlation 
(0.4) with solubility. This suggests that there are many factors that influence 
the solubility of PBIs and the dihedral angle is a contributing factor. 
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Further SAR studies can be carried out to expand the structural diversity of 
the analogues. This may aid in finding compounds that combine good in vitro 
potency with acceptable drug-like properties. 
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CHAPTER 3:  CONCLUSION 
 
3.1 General Summary and Conclusion 
 
SAR studies were carried out on the PBI scaffold. Analogues were synthesized 
in an attempt to address the solubility liability previously identified in the lead 
compound (20).  
 
A straight forward organic synthetic approach was utilized in the synthesis of the 
PBI target compounds. The identity and purity of these compounds were 
confirmed through characterization using analytical and spectroscopic 
techniques such as 1H and 13C NMR Spectroscopy, mass spectrometry (LC-
MS), reverse-phase HPLC and melting point. 
 
The solubility of target compounds was experimentally investigated using 
equilibrium and kinetic solubility assays. All compounds were evaluated for in 
vitro antiplasmodial activity, cytotoxicity and BHI activity. Selected compounds 
were also evaluated for metabolic stability in mouse and human liver 
microsomes.   
 
i. Pharmacological evaluation  
• Compounds showed good antiplasmodial activity against the chloroquine 
sensitive (NF54) strain of Plasmodium falciparum with activity in the sub-
micromolar range. 
• Selected compounds with sub-micromolar activity against the chloroquine 
sensitive (NF54) strain were tested against the chloroquine resistant (K1) 
strain of Plasmodium falciparum and found to be equipotent against both 
strains, suggesting the absence of cross resistance.  
• Substitutions on the benzimidazole moiety of the PBI core improved 
activity up to 6-fold relative to the lead compound. 
• Compounds with the 2-aminoethyl-3-pyrrolidinol side-chain showed 
improved activities compared to the corresponding N-ethylethane-diamino 
analogues. 
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• Substitutions at the C-2 position resulted in a decrease in antiplasmodial 
activity and altered the ability of these compounds to inhibit the formation 
of β-hematin. A plot of antiplasmodial activity and BHI displayed a positive 
albeit weak correlation between the BHI activity of compounds and 
antiplasmodial potency. This suggests that BHI is a contributing 
mechanism to the antiplasmodial activity of these compounds.  
• Substitution at the C-2 position resulted in PBI derivatives with low 
metabolic stability relative to the unsubstituted compounds (Figure 3.1). 
 
 
 
 
Figure 3.1: General structure of the PBI scaffold. 
 
ii. Solubility 
• Solubility was significantly improved upon introduction of a fluorine or 
methyl substituent at the C-2 position. 
• Single crystals of 6.4 were grown and analysed by X-ray diffraction in an 
effort to measure the dihedral angle and determine whether or not 
improvements in solubility were related to an increase in dihedral angle. 
• DFT calculations were used to obtain the dihedral angles for the 
optimized structures of all the PBI target compounds in order to determine 
the effect of structural modifications on dihedral angle and the 
consequential effect on solubility. The reliability of the optimized 
structures was confirmed by superimposing the single X-ray crystal 
structure of 6.4 with its corresponding optimized structure and a RMSD 
value of 0.156 was obtained.  
• The optimized structure of 6.4 suggests that the C-2 substituted 
compounds displayed an increase in the dihedral angle relative to the 
corresponding unsubstituted analogues as expected.  
• A weak trend (R2 = 0.4) between equilibrium solubility and dihedral angle 
suggests that many factors may influence the solubility of PBIs and that 
dihedral angle is just one of the contributing factors. 
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3.2 Future Outlook 
 
Further SAR studies to expand the chemical diversity of these compounds could 
lead to compounds that combine good antiplasmodial potency with desirable 
drug-like properties. Reactive metabolite studies should be carried out on the 
Mannich base analogues. As seen in scheme 7, these analogues have the same 
side chain as the antimalarial drug Amodiaquine. Studies have shown that 
Amodiaquine undergoes metabolism to form the cytotoxic amodiaquine 
quinoneimine that has been associated with hepatotoxicity and 
agranulocytosis.74,75 
 
 
 
 
 
 
 
 
 
 
Scheme 7: Metabolism of Amodiaquine to form the reactive metabolite 
amodiaquine quinoneimine (A); and the Mannich Base side-chain derivatives 
that have potential to form reactive metabolites (B). 
 
The crystal structure of other analogues, in particular the methyl substituted and 
the unsubstituted analogues, can be investigated in an effort to compare their 
dihedral angles with that of the fluorine-substituted crystal structure (6.4) 
obtained in this project and thus provide further validation of the DFT calculated 
optimized structures (Figure 3.2). 
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Figure 3.2: Structure of 6.4 
 
Since the 2-aminoethyl-3-pyrrolidinol analogues were obtained as a racemic 
mixture, the individual enantiomers can be synthesized and in vitro 
antiplasmodial activity investigated to determine if the individual enantiomers 
(Figure 3.3) possess different potencies. 
 
 
 
 
 
 
 
Figure 3.3: The (S)-enantiomer (i) and (R)-enantiomer (ii) of the 2-aminoethyl-3-
pyrrolidinol analogues. 
 
From the results found in this study, compound 6.8 displayed the most potent 
antiplasmodial activity (IC50 = 0.02 µM), 6.7 displayed the highest metabolic 
stability (>90 % remaining after 30 minutes) and 6.9 was found to be the most 
soluble (>200 µM) in the equilibrium solubility assay (Figure 3.4).  
 
 
 
 
 
 
Figure 3.4: The structures of compounds 6.7, 6.8 and 6.9. 
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Although compounds 6.7 and 6.8 outshone in the respective assays, they fell 
short in the solubility assay (see Table 8). As seen in Table 8, compound 6.4 
(Figure 3.2), displayed a combination of good antiplasmodial activity (IC50 = 0.19 
µM) and moderate solubility (80 µM). Since the benzimidazole moiety of this 
compound is currently unexplored, these substitutions could potentially improve 
the activity and metabolic stability as seen in other analogues such as 6.7 - 6.9 
(Figure 3.5). Additionally, metabolite identification can be done on this 
compound in order to identify the metabolites so that they can be synthesized 
and tested for antiplasmodial activity.   
 
Table 8: Biological and Solubility Data for Selected PBI Target Compounds* 
Compound 
Antiplasmodial 
Activity (NF54) 
IC50 (µM) 
Metabolic Stability 
in MLM:                   
% remaining after 
30 min 
Equilibrium 
Solubility: 
PBS (pH 6.5) μM 
6.7 0.78 91 23.4 (± 1.2) 
6.8 0.02 81 10 
6.9 3.95 NDa >200 
6.4 0.19 37 80 
*Green = good result; orange = moderate result; red = poor result 
aND: Not determined 
 
 
 
 
 
 
 
Figure 3.5:  Compound 6.4 and proposed structures for future work. 
 
Overall, more structurally diverse analogues are required in order to have more 
data points and obtain a broader understanding of the observed trends. 
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CHAPTER 4: EXPERIMENTAL 
 
4.1 Reagents, Solvents and Equipment	
	
All commercially available chemicals were purchased from Sigma-Aldrich, 
Merck or Combi-Blocks Limited and were of analytical grade, thus used 
without further purification. Reported compounds were characterized using 1H 
NMR, 13C NMR, HPLC-MS and melting point determination.  
1H NMR spectra were recorded on a Varian Mercury (300 MHz), a Bruker 
Ultrashield-Plus (400 MHz) spectrometer or a Bruker (600 MHz). Fluorine 
decoupled 13C NMR spectra were recorded on the same instruments at 101 
MHz or 151 MHz and 19F spectra were recorded at 377 MHz. NMR samples 
were dissolved in deuterated dimethylsulfoxide (DMSO-d6), methanol 
(CD3OD) or chloroform (CDCl3). Chemical shifts (δ) are reported in parts per 
million (ppm) to 2 decimal places. Coupling constants (J) are reported in Hertz 
(Hz) to one decimal place. Abbreviations used in assigning 1H-NMR signals 
are: d (doublet), dd (doublet of doublets), ddd (doublet of doublet of doublets), 
dt (doublet of triplets), m (multiplet), q (quartet), s (singlet), t (triplet) or td 
(triplet of doublets).  
Target compounds’ peak purities and mass spectrometry were determined on 
an Agilent HPLC system equipped with Agilent 1260® Infinity Binary Pump, 
Agilent 1260® Infinity Diode Array Detector, Agilent 1290® Infinity Column 
Compartment, Agilent 1260® Infinity Autosampler, Agilent 6120® Quadrupole 
LC/MS and Peak Scientific® Genius 1050 Nitrogen Generator. The column 
used was a Kinetex Core C18, 2.6 µm, 3.0 mm (ID) x 50 mm (length) 
maintained at 40 °C. Table 9 lists the composition and gradient conditions of 
the mobile phase used at a flow rate of 0.9 mL/min. The injection volume was 
2 μL while the mass spectra were obtained both by positive mode Electron 
Spray Ionization (ESI) and Atmospheric Pressure Chemical Ionization (APCI). 
The diode array detector was programmed to scan the eluents at an 
absorption wavelength range of 210-640 nm.  
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Table 9: HPLC Gradient Conditions 
Time (min) % A % B 
Composition 
A B 
0.00-1.00 80 20 10mM 
NH4OAc in 
buffer (0.4% 
acetic acid)       
10mM 
NH4OAc 
(0.4% acetic 
acid) in          
90% HPLC 
grade CH3OH 
in H2O 
1.00-3.00 0 100 
3.00-4.50 0 100 
4.50-5.20 80 20 
5.20-6.00 80 20 
 
Melting points were determined using a Stuart Automatic Melting Point 
Apparatus, SMP40 (Bibby Scientific) or Reichert-Jung Thermovar hot stage 
microscope and are uncorrected.  
Reactions were monitored by thin layer chromatography (TLC) using Fluka or 
Merck F254 aluminium-backed pre-coated silica gel plates and were 
visualized under ultraviolet light at 254 or 366 nm. Silica gel column 
chromatography was performed using Merck kieselgel 60: 70-230 mesh by 
gravity column chromatography or flash column chromatography on a Biotage 
IsoleraTM system (Biotage AB, Uppsala, Sweden).  
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4.2 Synthesis and Characterization  
General procedure for the synthesis of compound 2.1 
Ethyl(4-trifluromethylbenzoyl)acetate (1.0 equiv.) was added to a stirring 
solution of methyl iodide (2.0 equiv.) and  potassium carbonate (2.0 equiv.) in 
acetonitrile (9.0 mL). The mixture was heated to 50°C for 2 hours. The mixture 
was cooled to room temperature and the solvent was removed in vacuo. The 
residue was diluted with ethyl acetate, washed with water, dried with 
anhydrous sodium sulfate and concentrated in vacuo. The residue was 
purified by flash column chromatography (EtOAc/Hex) to obtain compound 
2.1. 
Ethyl 2-methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)propanoate, 2.1 
Colorless oil (0.554 g, 52 %); Rf 0.27 (10 % 
EtOAc-Hex); 1H NMR (300 MHz, CDCl3) δ 
8.10 (d, J = 8.2 Hz, 2H, ArH8,10), 7.76 (d, J = 
8.2 Hz, 2H, ArH7,11), 4.38 (q, J = 7.1 Hz, 1H, 
H4), 4.17 (q, J = 7.2 Hz, 2H, H2), 1.53 (d, J = 
7.1 Hz, 3H, H12), 1.19 (t, J = 7.2 Hz, 3H, H1); 
13C NMR (101 MHz, DMSO-d6) δ 197.6, 173.1, 141.5 (2C), 136.9, 131.5 (2C), 
128.5 (2C), 64.3, 51.5, 16.6, 16.2; MS: m/z 275.1 [M+H]+. 
 
General procedure for the synthesis of compound 2.2 
Ethyl(4-trifluromethylbenzoyl)acetate (1.0 equiv.) was added to Selectfluor 
fluorinating agent (2.0 equiv.) in acetonitrile (3.0 mL). The mixture was heated 
in the microwave at 82°C for 10 minutes. The black precipitate was filtered off 
and the solvent was removed in vacuo. The residue was purified by flash 
column chromatography (EtOAc-Hex) to acquire compound 2.2. 
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Ethyl 2-fluoro-3-oxo-3-(4-(trifluoromethyl)phenyl)propanoate 2.2  
Yellow oil (2.315 g, 66 %); Rf 0.33 (10 % 
EtOAc-Hex); 1H NMR (400 MHz, CDCl3) δ 
8.17 (d, J = 8.2, 2H, ArH8,10), 7.79 (d, J = 8.2 
Hz, 2H, ArH7,11), 5.86 (d, J = 48.8 Hz, 1H, H4), 
4.33 (q, J = 7.1 Hz, 2H, H2), 1.29 (t, J = 7.1 
Hz, 3H, H1); 13C NMR (101 MHz, CDCl3) δ 
188.8, 164.3, 136.0, 129.9, 129.9, 125.9, 125.8, 122.0, 91.3, 89.3, 62.9, 13.9; 
19F NMR (377 MHz, CDCl3) δ -63.49, -190.44; MS: m/z 277.0 [M-H]-. 
General procedure for the synthesis of compounds 2.3 
To a suspension of potassium tertiary butoxide (1.2 equiv.) in anhydrous THF 
(2 mL/mmol), ethyl acetoacetate (1.1 equiv.) and tertiary butanol (0.1 equiv.) 
were added at 0°C under nitrogen and the clear yellow solution was left to stir 
for 30 minutes. The appropriate benzyl halide (1.0 equiv.) was added 
dropwise at 0°C. The reaction was left to stir at 70°C for 8 – 24 hours. The 
reaction was quenched with water and saturated aqueous sodium 
bicarbonate. The organic layer was extracted with ethyl acetate (2 x 10 mL), 
after which the organic extracts were collected and dried with magnesium 
sulfate and concentrated in vacuo. The residue was purified by flash column 
chromatography (EtOAc-Hex) to obtain the desired intermediates, 2.3.1 – 
2.3.4. 
Ethyl 2-benzyl-3-oxobutanoate (2.3.1)  
Colorless oil (0.342 g, 7 %); Rf 0.46 (20 % EtOAc-Hex); 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.18 (m, 5H, 
ArH9,10,11,12,13), 4.17 (q, J = 7.6 Hz, 2H, H2), 3.80 (t, J = 
7.6 Hz, 1H, H4), 3.19 (dd, J = 7.6, 1.5 Hz, 2H, H7), 2.21 
(s, 3H, H6), 1.22 (t, J = 7.6 Hz, 3H, H1); 13C NMR (101 
MHz, CDCl3) δ 202.4, 169.1, 138.2, 128.8 (2C), 128.6 
(2C), 126.7, 61.4, 61.3, 44.0, 29.5, 14.00; MS: m/z 221.1 
[M+H]+.  
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Ethyl 2-(4-chlorobenzyl)-3-oxobutanoate (2.3.2) 
Yellow oil (2.339 g, 60 %); Rf 0.61 (30 % EtOAc-Hex); 
1H NMR (400 MHz, CDCl3) δ 7.29 – 7.25 (m, 2H, 
ArH10,12), 7.15 – 7.12 (m, 2H, ArH9,13), 4.17 (q, J = 7.2, 
Hz, 2H, H2), 3.75 (t, J = 7.6 Hz, 1H, H4), 3.15 (dd, J = 
7.6, 3.5, 2H, H7), 2.22 (s, 3H, H6), 1.23 (t, J = 7.2 Hz, 
3H, H1); 13C NMR (101 MHz, CDCl3) δ 201.9, 168.9, 
136.7, 131.4, 130.2 (2C), 128.7 (2C), 61.7, 61.2, 33.2, 
29.5, 14.0; MS: m/z 253.0 [M-H]-.  
Ethyl 2-(3-chlorobenzyl)-3-oxobutanoate (2.3.3) 
Yellow oil (3.283 g, 84 %); Rf 0.56 (15 % EtOAc-Hex); 1H 
NMR (400 MHz, CDCl3) δ 7.23 – 7.19 (m, 4H, 
ArH9,11,12,13), 4.18 (q, J = 7.3, 2H, H2), 3.76 (dd, J = 7.6, 
7.3 Hz, 1H, H4), 3.19 – 3.13 (m, 2H, H7), 2.23 (s, 3H, 
H6), 1.23 (t, J = 7.3 Hz, 3H, H1); 13C NMR (101 MHz, 
CDCl3) δ 201.7, 168.8, 140.3, 134.3, 130.2, 129.8, 
127.0, 126.9, 61.6, 61.0, 33.4, 29.5, 14.0; MS: m/z 
254.07 [M]+. 
 
Ethyl 2-(2-chlorobenzyl)-3-oxobutanoate (2.3.4) 
Yellow oil (2.311 g, 59 %); Rf 0.53 (15 % EtOAc-Hex); 1H 
NMR (400 MHz, CDCl3) δ 7.38 – 7.35 (m, 1H, ArH10), 
7.29 – 7.25 (m, 1H, ArH12), 7.20 – 7.17 (m, 2H, ArH11,13), 
4.23 – 4.11 (m, 2H, H2), 3.97 (dd, J = 8.3, 6.6 Hz, 1H, 
H4), 3.35 – 3.23 (m, 2H, H7), 2.25 (s, 3H, H6), 1.23 (t, J = 
7.1 Hz, 3H, H1); 13C NMR (101 MHz, CDCl3) δ 202.1, 
168.9, 135.8, 134.1, 131.6, 129.6, 128.3, 126.9, 61.5, 
58.8, 31.9, 29.6, 14.0; MS: m/z 254.06 [M]+.  
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General procedure for the synthesis of compound 3.2 
4-5-Dichloro-o-phenylenediamine (1.0 equiv.) was added to ethyl-2- 
cyanoacetate (3.0 equiv.) in DMF (1.5 mL). The solution was heated to 150°C 
for 2 hours. The organic layer was extracted with ethyl acetate and the 
organic extracts were combined, washed with water, brine, dried with 
anhydrous magnesium sulfate and concentrated in vacuo. The residue was 
purified by flash column chromatography (EtOAc-Hex) to obtain the required 
compound 3.1. 
2-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)acetonitrile (3.2) 
Red/brown solid (1.645 g, 57 %); %); m.p. 274 - 278 
οC; Rf 0.35 (50 % EtOAc-Hex); 1H NMR (400 MHz, 
DMSO-d6) δ 12.91 (s, 1H, NH), 7.86 (s, 2H, ArH5,8), 
4.43 (s, 2H, H2); 13C NMR (101 MHz, DMSO-d6) δ 
148.4, 145.2, 143.4, 120.4, 116.7, 116.0, 113.5, 
110.2, 18.9; HPLC-MS (APCI/ESI): Purity = 99%, tR = 
3.18 min, MS: m/z 226.0 [M+H]+. 
General procedure for the synthesis of compound 3.3 
A mixture of 4,5-difluorobenzene-1,2-diamine (1.0 equiv.) and ethyl-2-
cyanoacetate (2.0 equiv.) was heated in the microwave at 110°C for 15 
minutes. The residue was purified by flash column chromatography (EtOAc-
Hex) to obtain the required compound 3.2. 
2-(5,6-difluoro-1H-benzo[d]imidazol-2-yl)acetonitrile (3.3) 
Red/brown solid (0.485 g, 60 %); m.p. 267 - 269 οC; Rf 
0.38 (70 % EtOAc-Hex); 1H NMR (400 MHz, DMSO-
d6) δ 12.80 (s, 1H, NH), 7.67 – 7.59 (m, 2H, ArH5,8), 
4.39 (s, 2H, H2); 13C NMR (101 MHz, DMSO-d6) δ 
148.5, 148.3, 147.4, 146.1, 146.0, 116.8, 106.1, 
100.6, 18.9; HPLC-MS (APCI/ESI): Purity = 99%, tR = 1.32 min, MS: m/z 
194.1 [M+H]+. 
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General procedure for the synthesis of the hydroxy intermediates (4.1 – 
4.11) 
A mixture of the appropriate 2-benzimidazole acetonitrile (1.0 equiv.), 
ammonium acetate (2 equiv.) and the appropriate β-keto ester (1.2 equiv.) 
was heated to reflux at 145°C for 1-4 hours. The suspension was cooled to 
75°C before acetonitrile (10 mL) was added and the mixture was allowed to 
stir for 15 minutes. The mixture was cooled to room temperature and cooled 
on ice. The cold mixture was filtered and the precipitate washed with cold 
acetonitrile (4x10 mL), dried in vacuo and used without further purification. 
 
1-hydroxy-2-methyl-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (4.1)  
Obtained from 2.1 (0.787 g, 2.87 mmol, 1.2 
equiv.), 3.1 (0.376 g, 2.39 mmol, 1.0 equiv.) 
and NH4OAc (0.369 g, 4.79 mmol, 2.0 equiv.) 
as a brown solid (0.132 g, 28 %); m.p. 299 -
301 °C; Rf 0.48 (50 % EtOAc-Hex); 1H NMR 
(400 MHz, DMSO-d6) δ 13.58 (s, 1H, OH), 
8.66 (dt, J = 8.2, 1.0 Hz, 1H, ArH9), 7.93 (d, J 
= 8.0 Hz, 2H, ArH13,15), 7.65 (d J = 8.0 Hz, 2H, ArH12,16), 7.58 – 7.55 (m, 2H, 
ArH6,7), 7.45 – 7.36 (m, 1H, ArH8), 1.88 (s, 3H, H17); 13C NMR (101 MHz, 
DMSO-d6) δ 159.3, 148.3, 145.9, 141.8, 132.3, 129.9 (2C), 129.4, 128.1, 
127.3, 126.0, 126.0 (2C), 123.3, 122.9, 117.1, 116.8, 111.8, 111.6, 13.6; 
HPLC-MS (APCI/ESI): Purity = 99%, tR = 4.48 min, MS: m/z 368.1 [M+H]+. 
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Exact Mass: 367.09
Mol. Wt: 367.33
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2-fluoro-1-hydroxy-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (4.2)  
Obtained from 2.2 (0.626 g, 2.25 mmol, 1.2 
equiv.), 3.1 (0.295 g, 1.88 mmol, 1.0 equiv.) 
and NH4OAc (0.289 g, 3.75 mmol, 2.0 equiv.) 
as a brown solid (0.416 g, 57 %); m.p. 343 - 
348 °C; Rf 0.43 (50 % EtOAc-Hex); 1H NMR 
(400 MHz, DMSO-d6) δ 13.81 (s, 1H, OH), 
8.60 (dt, J = 8.2, 1.0 Hz, 1H, ArH9), 7.98 (d, J 
= 7.8 Hz, 2H, ArH13,15), 7.82 (d, J = 7.8 Hz, 2H, ArH12,16), 7.60 – 7.57 (m, 2H, 
ArH6,7), 7.43 (ddd, J = 8.0, 8.0, 4.0 Hz 1H, ArH8); 13C NMR (101 MHz, DMSO-
d6) δ 152.5, 152.2, 144.6, 139.6, 137.3, 135.7, 134.7, 134.6, 132.8, 130.7, 
128.4, 128.4, 127.7, 126.1, 126.1, 123.0, 116.6, 116.4, 112.2; HPLC-MS 
(APCI/ESI): Purity = 97%, tR = 4.20 min,  MS: m/z 372.0 [M+H]+. 
 
 
1-Hydroxy-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (4.3) 
Obtained from ethyl(4-trifluromethylbenzoyl)-
acetate (0.994 g, 3.82 mmol, 1.2 equiv.), 3.1 
(0.500 g, 3.18 mmol, 1.0 equiv.) and NH4OAc 
(0.490 g, 6.36 mmol, 2.0 equiv.) as a silver 
tan powder (0.850 g, 76%); Rf 0.61 (70 % 
EtOAc-Hex); m.p. 341 - 342 οC; 1H NMR (400 
MHz, DMSO-d6) δ 8.59 (d, J = 8.1 Hz, 1H, 
ArH9), 7.91 (d, J = 8.2 Hz, 2H, ArH13,15), 7.85 
(d, J = 8.2 Hz, 2H, ArH12,16), 7.56 (m, 2H, ArH6,7), 7.40 (t, J = 8.1 Hz, 1H, 
ArH8), 6.09 (s, 1H, H2); 13C NMR (100 MHz, DMSO-d6) δ 158.3, 151.5, 147.9, 
141.4, 132.4, 130.4, 129.6, 128.1, 127.3 (C2), 126.0 (C2), 123.1 (C2), 117.0, 
116.7, 112.1(C2) and 105.2; MS: m/z 354 [M+H]+. 
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Mol. Wt.: 353.30
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7,8-dichloro-2-fluoro-1-hydroxy-3-(4-(trifluoromethyl)phenyl)benzo-
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (4.4) 
Obtained from 3.2 (0.670 g, 2.96 mmol, 
1.0 equiv.), 2.2 (0.990 g, 3.56 mmol, 1.2 
equiv.) and NH4OAc (0.457 g, 5.93 mmol, 
2.0 equiv.) as a dark green solid (0.663 g, 
51 %); m.p. 299 - 301 °C; Rf 0.35 (50 % 
EtOAc-Hex); 1H NMR (400 MHz, DMSO-
d6) δ 8.65 (s, 1H, ArH9), 7.94 (d, J = 7.8 
Hz, 2H, ArH13,15), 7.79 (d, J = 7.8 Hz, 2H, 
ArH12,16), 7.76 (s, 1H, ArH6); 13C NMR (101 MHz, DMSO-d6) δ 165.7, 152.5, 
139.4 (2C), 136.6 (2C), 130.7, 129.6, 128.7, 125.9, 125.9, 122.2, 119.9, 116.9 
(2C), 115.6, 106.5, 101.1, 88.6; HPLC-MS (APCI/ESI): Purity = 99%, tR = 4.84 
min, MS: m/z 440.8 [M+H]+. 
 
7,8-dichloro-1-hydroxy-3-(4-(trifluoromethyl)phenyl)benzo-
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (4.5)  
Obtained from 3.2 (0.504 g, 2.23 mmol, 
1.0 equiv.), ethyl(4-trifluromethyl-
benzoyl)acetate (0.55 mL, 2.68 mmol, 1.2 
equiv.) and NH4OAc (0.343 g, 4.46 mmol, 
2.0 equiv.) as a brown solid (0.787 g, 84 
%); m.p. 305 - 307 °C; Rf 0.41 (60 % 
EtOAc-Hex); 1H NMR (400 MHz, DMSO-
d6) δ 8.66 (s, 1H, ArH9), 7.91 (d, J = 8.1 
Hz, 2H, ArH13,15), 7.84 (d, J = 8.1 Hz, 2H, ArH12,16), 8.66 (s, 1H, ArH6), 6.05 (s, 
1H, H2). 13C NMR (101 MHz, DMSO-d6) δ 158.5, 151.9, 150.0, 141.6, 134.7, 
130.4, 130.0, 129.6 (2C), 129.2, 128.1, 126.0, 126.0, 124.2, 123.2, 117.3, 
117.2, 114.0, 104.4; HPLC-MS (APCI/ESI): Purity = 95%, tR = 5.36 min, MS: 
m/z 422.1 [M+H]+.  
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2,7,8-trifluoro-1-hydroxy-3-(4-(trifluoromethyl)phenyl)benzo-
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (4.6)  
Obtained from 3.3 (0.460 g, 2.38 mmol, 1.0 
equiv.), 2.2 (0.795 g, 2.86 mmol, 1.2 
equiv.) and NH4OAc (0.367 g, 4.76 mmol, 
2.0 equiv.) as a dark green solid (0.498 g, 
51 %); m.p. 292 - 296 °C; Rf 0.26 (50 % 
EtOAc-Hex); 1H NMR (400 MHz, DMSO-
d6) δ 8.45 (dd, J = 8.0, 4.0 Hz, 1H, ArH9), 
7.92 (d, J = 8.1 Hz, 2H, ArH13,15), 7.78 (d, J 
= 8.1 Hz, 2H, ArH12,16), 7.57 (dd, J = 8.0, 4,0 Hz, 1H, ArH6); 13C NMR (101 
MHz, DMSO-d6) δ 152.9, 152.6, 150.1, 149.9, 137.2, 136.6, 136.1, 135.9, 
130.7, 130.0, 129.7, 125.8, 125.8, 123.2, 118.5, 104.2, 104.0, 103.1, 102.9; 
HPLC-MS (APCI/ESI): Purity = 99%, tR = 5.06 min, MS: m/z 406.1 [M-H]-. 
 
7,8-difluoro-1-hydroxy-3-(4-(trifluoromethyl)phenyl)benzo-
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (4.7)  
Obtained from 3.3 (0.244 g, 1.26 mmol, 
1.0 equiv.), ethyl(4-trifluromethyl-
benzoyl)acetate (0.30 mL, 1.52 mmol, 1.2 
equiv.) and NH4OAc (0.194 g, 2.52 mmol, 
2.0 equiv.) as a grey/brown solid (0.306 g, 
62 %); m.p. 289 - 294 °C; Rf 0.61 (70 % 
EtOAc-Hex); 1H NMR (400 MHz, DMSO-
d6) δ 8.52 (dd, J = 10.0, 7.0 Hz, 1H ArH9 ), 
7.91 (d, J = 8.1 Hz, 2H, ArH13,15), 7.84 (d, J = 8.1 Hz, 2H, ArH12,16), 7.63 (dd, J 
= 10.0, 7.0 Hz, 1H ArH6 ), 6.11 (s, 1H, ArH2). 13C NMR (101 MHz, DMSO- d6) 
δ 158.1, 151.8, 149.1, 141.3, 130.5, 130.2, 129.6, 129.1, 129.0, 126.1, 126.1, 
123.7, 123.6, 116.7, 105.7, 105.5, 105.1, 101.2, 101.0; HPLC-MS (APCI/ESI): 
Purity = 99%, tR = 5.05 min, MS: m/z 388.0 [M-H]-. 
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Mol. Wt.: 389.29
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2-benzyl-1-hydroxy-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (4.8) 
Obtained from 2.3 (0.262 g, 1.19 mmol, 1.2 
equiv.), 3.1 (0.156 g, 0.99 mmol, 1.0 equiv.) 
and NH4OAc (0.153 g, 1.98 mmol, 2.0 equiv.) 
as a brown solid (0.243 g, 78 %); m.p. 245 - 
249 °C Rf 0.58 (50 % EtOAc-Hex); 1H NMR 
(400 MHz, DMSO-d6) δ 13.45 (s, 1H, OH), 
8.60 (dt, J = 8.1, 1.0 Hz, 1H, ArH9), 7.54 – 
7.49 (m, 2H, ArH6,7), 7.35 (ddd, J = 8.0, 8.0, 4.0 Hz 1H, ArH8), 7.27 – 7.21 (m, 
4H, ArH13,14,16,17), 7.17 – 7.12 (m, 1H, ArH15), 3.97 (s, 2H, H11), 2.35 (s, 3H, 
H18); 13C NMR (101 MHz, DMSO-d6) δ 159.2, 147.5, 146.0, 140.9, 132.3, 
128.7 (2C), 128.4 (2C), 128.3, 127.0, 126.2, 122.6, 117.3, 116.7, 114.9, 111.7 
(2C), 31.6, 18.8; HPLC-MS (APCI/ESI): Purity = 99%, tR = 4.43 min, MS: m/z 
314.1 [M+H]+.  
 
2-(4-chlorobenzyl)-1-hydroxy-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (4.9)  
Obtained from 2.3 (2.339 g, 9.18 mmol, 1.2 
equiv.), 3.1 (1.202 g, 7.65 mmol, 1.0 equiv.) 
and NH4OAc (1.180 g, 15.31 mmol, 2.0 
equiv.) as a light brown solid (1.904 g, 72 
%); m.p. 109 - 114 °C; Rf 0.78 (50 % EtOAc-
Hex); 1H NMR (400 MHz, DMSO-d6) δ 8.58 
(ddd, J = 8.1, 1.2, 0.7 Hz, 1H, ArH9), 7.54 – 
7.44 (m, 2H, ArH6,7), 7.30 – 7.24 (m, 5H, ArH8,13,14,16,17), 3.95 (s, 2H, H11), 
2.34 (s, 3H, H18); 13C NMR (101 MHz, DMSO-d6) δ 172.4, 159.6, 147.6, 
147.4, 140.5, 135.2, 132.3, 130.7, 130.3, 128.9, 128.6, 126.4, 126.0, 121.6, 
118.2, 116.5, 112.7, 112.5, 31.1, 18.8; HPLC-MS (APCI/ESI): Purity = 83%, tR 
= 5.33 min, MS: m/z 348.0 [M+H]+. 
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2-(3-chlorobenzyl)-1-hydroxy-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (4.10) 
Obtained from 2.3 (3.179 g, 12.48 mmol, 1.2 
equiv.), 3.1 (1.634 g, 10.40 mmol, 1.0 equiv.) 
and NH4OAc (1.603 g, 20.80 mmol, 2.0 equiv.) 
as a brown solid (3.294 g, 91 %); m.p. 211 -
215 °C; Rf 0.60 (50 % EtOAc-Hex); 1H NMR 
(400 MHz, DMSO-d6) δ 8.59 (dt, J = 8.1, 1.0 
Hz, 1H, ArH9), 7.54 – 7.45 (m, 2H, ArH6,7), 
7.31 – 7.26 (m, 3H, ArH8,15,17), 7.23 - 7.16 (m, 2H, H13,14), 3.98 (s, 2H, H11), 
2.35 (s, 3H, H18); 13C NMR (101 MHz, DMSO-d6) δ 172.4, 159.6, 147.8, 
147.3, 144.1, 133.4, 130.5 (2C), 128.8, 128.2, 127.2, 126.4, 126.2, 121.7, 
118.1, 116.5, 112.6, 112.3, 31.4, 18.8; HPLC-MS (APCI/ESI): Purity = 87%, tR 
= 4.88 min, MS: m/z 348.0 [M+H]+. 
2-(2-chlorobenzyl)-1-hydroxy-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-
4-carbonitrile (4.11) 
Obtained from 2.3 (2.240 g, 8.79 mmol, 1.2 
equiv.), 3.1 (1.152 g, 7.33 mmol, 1.0 equiv.) 
and NH4OAc (1.130 g, 14.66 mmol, 2.0 equiv.) 
as a grey/brown solid (2.176 g, 85 %); m.p. 
319 - 325 °C; Rf 0.80 (50 % EtOAc-Hex); 1H 
NMR (400 MHz, DMSO-d6) δ 13.34 (s, 1H, 
OH), 8.59 (d, J = 8.2 Hz, 1H, ArH9), 7.58 – 
7.50 (m, 2H, ArH6,7), 7.45 (d, J = 7.8 Hz, 1H, ArH14), 7.38 – 7.33 (m, 1H, 
ArH8), 7.23 – 7.13 (m, 2H, ArH15,16), 6.97 (d, J = 7.6 Hz, 1H, ArH17), 4.05 (s, 
2H, H11), 2.30 (s, 3H, H18); 13C NMR (101 MHz, DMSO-d6) δ 159.1, 148.4, 
147.4, 146.4, 137.7, 133.6, 132.4, 129.5, 129.1, 128.4, 128.0, 127.6, 127.0, 
122.7, 117.1, 116.7, 112.8, 111.8, 29.4, 18.6; HPLC-MS (APCI/ESI): Purity = 
99%, tR = 4.82 min, MS:  m/z 348.0 [M+H]+. 
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General procedure for the synthesis of the chlorinated intermediates 
(5.1 – 5.11) 
A mixture of the appropriate hydroxy intermediate (1.0 equiv.) and POCl3 (20 
equiv.) was heated to 130°C for 2-8 hours. Excess POCl3 was removed by 
distillation, cold water (20 mL) was added to the brown residue and the 
mixture was stirred at room temperature for 15 minutes. The mixture was 
neutralized with saturated sodium bicarbonate solution and filtered. The solid 
was washed with cold water (4x10 mL), dried in vacuo and used without 
further purification. 
1-chloro-2-methyl-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (5.1)  
Obtained from 4.1 (0.312 g, 0.85 mmol, 1.0 
equiv.) and POCl3 (1.58 mL, 17.0 mmol, 20 
equiv.) as a yellow/brown solid (0.300 g, 92 
%); m.p. 289 - 291°C; Rf 0.59 (30 % EtOAc-
Hex); 1H NMR (400 MHz, DMSO-d6) δ 8.78 
(d, J = 8.0 Hz, 1H,H9), 8.02 – 7.98 (m, 3H, 
H6,13,15), 7.78 (d, J = 8.0 Hz, 2H, ArH12,16), 
7.69 (t, J = 7.7 Hz, 1H, ArH7), 7.53 (t, J = 8.0 Hz, 1H, ArH8), 2.20 (s, 3H, H17); 
13C NMR (101 MHz, DMSO-d6) δ 150.6, 146.2, 145.0, 140.4, 133.8, 130.3, 
130.2, 127.3, 126.3 (2C), 126.2, 122.8 (2C), 120.3, 118.1, 116.5, 114.9 (2C), 
99.9, 16.9; HPLC-MS (APCI/ESI): Purity = 95%, tR = 4.44 min; MS: m/z 386.1 
[M+H]+. 
1-chloro-2-fluoro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile (5.2) 
Obtained from 4.2 (0.730 g, 1.88 mmol, 1.0 
equiv.) and POCl3 (5.25 mL, 56.3 mmol, 30 
equiv.) as a yellow/brown solid (0.642 g, 84 
%); m.p. 281 - 285 °C; Rf 0.58 (30 % EtOAc-
Hex); 1H NMR (400 MHz, DMSO-d6) δ 8.73 
(dt, J = 8.6, 1.0 Hz, 1H, ArH9), 8.08 – 8.02 
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(m, 3H, ArH6,13,15), 7.96 (d, J = 8.0 Hz, 2H, ArH12,16), 7.73 (ddd, J = 8.6, 7.1, 
1.0 Hz, 1H, ArH7), 7.58 (ddd, J = 8.6, 7.1, 1.0 Hz, 1H, ArH8); 13C NMR (101 
MHz, DMSO-d6) δ 145.6, 145.5, 144.9, 144.7, 143.3, 132.4, 131.1, 130.6, 
127.8, 127.6, 126.3, 126.2, 126.0, 126.0, 123.4, 123.1, 116.7, 115.8, 112.2; 
19F NMR (377 MHz, DMSO-d6) δ -61.30, -155.54; HPLC-MS (APCI/ESI): 
Purity = >99%, tR = 5.13 min, MS: m/z 390.1 [M+H]+. 
1-Chloro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (5.3) 
Obtained from 4.3 (0.500 g, 1.42 mmol, 1.0 
equiv.) and POCl3 (2.63 mL, 28.3 mmol, 20 
equiv.) as a yellow solid (0.481 g, 91%); Rf 
0.53 (40 % EtOAc-Hex); M. pt. 247-248οC; 1H 
NMR (400 MHz, DMSO-d6) δ 8.66 (d, J = 8.4 
Hz, 1H, ArH9), 8.01 (m, 5H, ArH 6,12,13,15,16), 
7.67 (t, J = 8.4 Hz, 1H, ArH7), 7.58 (s, 1H, 
H2), 7.51 (t, J = 8.4 Hz, 1H, ArH8); 13C NMR 
(100 MHz, DMSO-d6) δ 148.2, 147.7, 144.9, 139.4, 135.2, 131.0, 130.4, 
129.7, 127.5, 126.3 (2C), 123.1 (2C), 120.7, 116.3, 115.4, 112.8 (2C) and 
97.5; MS: m/z 372:374 (3:1) [M+H]+. 
 
1,7,8-trichloro-2-fluoro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo-
[1,2-a]pyridine-4-carbonitrile (5.4) 
Obtained from 4.4 (0.740 g, 1.68 mmol, 
1.0 equiv.) and POCl3 (3.13 mL, 33.62 
mmol, 20 equiv.) as a green solid (0.617 
g, 80 %); m.p. 279 - 284 °C; Rf 0.89 (30 
% EtOAc-Hex); 1H NMR (400 MHz, 
DMSO-d6) δ 8.92 (s, 1H, ArH9), 8.41 (s, 
1H, ArH6), 8.08 (d, J = 8.0 Hz, 2H, 
ArH13,15), 7.97 (d, J = 8.0 Hz, 2H, 
ArH12,16); 13C NMR (101 MHz, DMSO-d6) δ 146.5, 146.1, 144.6, 143.7, 140.8, 
140.6, 134.0, 131.1, 130.6, 130.4, 129.8, 126.5, 125.7, 121.7, 117.5, 117.0, 
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114.1, 113.7, 99.1; HPLC-MS (APCI/ESI): Purity = 99%, tR = 5.51 min, MS: 
m/z 460.0 [M+H]+. 
1,7,8-Trichloro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile  (5.5)  
Obtained from 4.5 (0.758 g, 1.80 mmol, 
1.0 equiv.) and POCl3 (3.35 mL, 35.90 
mmol, 20 equiv.) as a brown solid (0.850 
g, 107 %); m.p. 253 - 255 °C; Rf 0.80 (70 
% EtOAc-Hex); 1H NMR (400 MHz, 
DMSO-d6) δ 8.86 (s, 1H, ArH9), 8.34 (s, 
1H, ArH6), 8.03 (m, 4H, ArH12,13,15,16), 
7.70 (s, 1H, H2); 13C NMR (150 MHz, 
DMSO-d6) δ 149.5, 149.4, 144.3, 139.1, 135.4, 134.7, 130.9, 130.4, 130.2, 
128.9, 126.4 (2C), 125.2, 125.1, 123.4, 121.2, 117.5, 115.0, 113.6; HPLC-MS 
(APCI/ESI): Purity = 99%, tR = 5.53 min, MS: m/z 440.0 [M+H]+.  
 
1-chloro-2,7,8-trifluoro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo-
[1,2-a]pyridine-4-carbonitrile (5.6)  
Obtained from 4.6 (0.850 g, 2.09 mmol, 
1.0 equiv.) and POCl3 (3.89 mL, 41.70 
mmol, 20 equiv.) as a green/brown solid 
(1.2208 g, 137 %); m.p. 253 - 260 °C; Rf 
0.66 (50 % EtOAc-Hex); 1H NMR (400 
MHz, DMSO-d6) δ 8.53 (dd, J = 10.0, 7.0 
Hz, 1H, ArH9), 7.98 (d, J = 8.3 Hz, 2H, 
ArH13,15), 7.80 (d, J = 8.3 Hz, 2H, 
ArH12,16), 7.67 (dd, J = 10.0, 7.0 Hz, 1H, ArH6); 13C NMR (101 MHz, DMSO-
d6) δ 152.1, 151.8, 145.6, 139.6, 137.3, 135.5, 135.1, 134.9, 131.1, 130.6 
(2C), 126.2, 126.1, 123.1, 115.9, 105.8, 105.5, 101.3, 101.1; HPLC-MS 
(APCI/ESI): Purity = 95%, tR = 5.19 min, MS: m/z 426.0 [M+H]+. 
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1-chloro-7,8-difluoro-3-(4-(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-
a]pyridine-4-carbonitrile  (5.7)  
Obtained from 4.7 (0.766 g, 1.97 mmol, 
1.0 equiv.) and POCl3 (3.67 mL, 39.40 
mmol, 20 equiv.) as a brown solid (0.700 
g, 87 %); m.p. 237 - 242 °C; Rf 0.77 (70 % 
EtOAc-Hex); 1H NMR (400 MHz, DMSO-
d6) δ 8.74 (dd, J = 11.0, 7.6 Hz, 1H, ArH9), 
8.13 (dd, J = 11.0, 7.6 Hz, 1H, ArH6), 8.02 
(s, 4H, ArH12,13,15,16), 7.64 (s, 1H, ArH2); 13C NMR (150 MHz, DMSO-d6) δ 
148.5, 141.2, 141.1, 139.3, 134.8, 130.4 (2C), 126.4, 126.4, 125.8, 125.1, 
125.0, 115.1, 113.3, 107.4, 107.2, 105.0, 104.8, 97.6; HPLC-MS (APCI/ESI): 
Purity = 96%, tR = 5.19 min, MS: m/z 408.0 [M+H]+. 
 
2-benzyl-1-chloro-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (5.8)  
Obtained from 4.8 (0.297 g, 0.95 mmol, 1.0 
equiv.) and POCl3 (2.65 mL, 28.4 mmol, 30 
equiv.) as a green/brown solid (0.328 g, 104 
%); m.p. 167 - 171 °C; Rf 0.63 (30 % EtOAc-
Hex); 1H NMR (400 MHz, DMSO-d6) δ 8.70 
(dt, J = 8.6, 0.9 Hz, 1H, ArH9), 7.95 (dt, J = 
8.6, 0.9 Hz, 1H, ArH6), 7.64 (ddd, J = 8.6, 7.1, 0.9 Hz, 1H, ArH7), 7.46 (ddd, J 
= 8.6, 7.1, 0.9 Hz, 1H, ArH8), 7.33 – 7.29 (m, 2H, ArH13,17), 7.25 – 7.21 (m, 
3H, ArH14,15,16), 4.34 (s, 2H, H11), 2.57 (s, 3H, H18); 13C NMR (101 MHz, 
DMSO-d6) δ 150.2, 146.7, 144.6, 137.7, 134.7, 130.6, 129.1 (3C), 128.2, 
127.0 (2C), 122.4, 121.3, 112.0, 116.6, 115.3, 99.9, 34.6, 20.0; HPLC-MS 
(APCI/ESI): Purity = 95%, tR = 4.71 min, MS: m/z 332.1 [M+H]+.  
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1-chloro-2-(4-chlorobenzyl)-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (5.9) 
Obtained from 4.9 (0.348 g, 5.30 mmol, 1.0 
equiv.) and POCl3 (14.8 mL, 159.1 mmol, 30 
equiv.) as a green/brown solid (2.107 g, 109 
%); m.p. 202 - 208 °C; Rf 0.41 (30 % EtOAc-
Hex); 1H NMR (400 MHz, DMSO-d6) δ 8.72 
(dt, J = 8.5, 0.9 Hz, 1H, ArH9), 7.98 – 7.93 
(m, 1H, ArH6), 7.68 – 7.64 (m, 1H, ArH7), 
7.50 – 7.46 (m, 1H, ArH8), 7.37 – 7.34 (m, 2H, ArH14,16), 7.25 (d, J = 8.4 Hz, 
2H, ArH13,17), 4.33 (s, 2H, H11), 2.55 (s, 3H, H18); 13C NMR (101 MHz, DMSO-
d6) δ 158.8, 151.6, 150.3, 144.3, 136.8, 135.6, 135.0, 130.1, 129.1, 128.6, 
127.1, 127.0, 122.9, 122.5, 119.8, 116.7, 105.3, 99.6,  33.9, 20.1; HPLC-MS 
(APCI/ESI): Purity = 86%, tR = 4.91 min, MS: m/z 366.0 [M+H]+. 
 
1-chloro-2-(3-chlorobenzyl)-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (5.10) 
Obtained from 4.10 (3.000 g, 12.21 mmol, 1.0 
equiv.) and POCl3 (22.8 mL, 244.2 mmol, 20 
equiv.) as a brown solid (2.987 g, 67 %); m.p. 
174 - 180 °C; Rf 0.46 (30 % EtOAc-Hex); 1H 
NMR (400 MHz, DMSO-d6) δ 8.69 (dt, J = 8.4, 
0.9 Hz, 1H, ArH9), 7.95 (dt, J = 8.4, 0.9 Hz, 
1H, ArH6), 7.64 (ddd, J = 8.4, 7.2, 0.9 Hz, 1H, 
ArH7), 7.46 (ddd, J = 8.4, 7.2, 0.9 Hz, 1H, ArH8), 7.33 – 7.28 (m, 3H, 
ArH13,15,17), 7.19 – 7.17 (m, 1H, ArH14), 4.35 (s, 2H, H11), 2.56 (s, 3H, H18); 13C 
NMR (101 MHz, DMSO-d6) δ 149.9, 146.8, 144.8, 140.4, 134.9, 134.0, 130.9, 
130.6, 128.1, 127.1, 126.9, 126.9, 122.3, 120.4, 120.0, 116.6, 115.3, 100.0, 
34.3, 20.0; HPLC-MS (APCI/ESI): Purity = 89%, tR = 4.94 min, m/z 366.0 
[M+H]+. 
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1-chloro-2-(2-chlorobenzyl)-3-methylbenzo[4,5]imidazo[1,2-a]pyridine-4-
carbonitrile (5.11)  
Obtained from 4.11 (0.933 g, 2.68 mmol, 1.0 
equiv.) and POCl3 (5.0 mL, 53.64 mmol, 20 
equiv.) as a yellow/brown solid (0.985 g, 100 
%); m.p. 268 - 271 °C; Rf 0.67 (30 % EtOAc-
Hex); 1H NMR (400 MHz, DMSO-d6) δ 8.69 
(d, J = 8.4 Hz, 1H, ArH9), 7.97 (d, J = 8.4 Hz, 
1H, ArH6), 7.65 (t, J = 8.4 Hz, 1H, ArH7), 7.54 (dd, J = 8.0, 1.4 Hz, 1H, ArH14), 
7.47 (ddd, J = 8.4, 7.0, 1.2 Hz, 1H, ArH8), 7.30 (t, J = 7.0 Hz, 1H, ArH15), 7.20 
(t, J = 7.0 Hz, 1H, ArH16), 6.97 (d, J = 7.0 Hz, 1H, ArH17), 4.36 (s, 2H, H11), 
2.54 (s, 3H, H18); 13C NMR (101 MHz, DMSO-d6) δ 149.9, 146.9, 144.9, 
140.7, 135.0, 133.6, 130.6, 129.9, 129.0, 128.9, 128.1, 127.0, 122.4, 120.1, 
120.0, 116.5, 115.2, 100.2, 32.7, 19.7; HPLC-MS (APCI/ESI): Purity = 97%, tR 
= 4.83 min, MS: m/z 366.0 [M+H]+. 
 
General procedure for the synthesis of target compounds (6.1 – 6.5; 6.7 
– 6.10; 6.12 - 6.15) 
The appropriate amine (2.0 equiv.) was added to a stirring solution of the 
appropriate chlorinated intermediate (1.0 equiv.) and triethylamine (2.0 equiv.) 
in THF (4.0 mL). The solution was heated in the microwave at 80°C for 20-40 
minutes. The solvent was removed in vacuo and the residue was purified by 
flash column chromatography (MeOH-DCM). The resulting solid was 
recrystallized from acetone. 
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Exact Mass: 365.05
Mol. Wt: 366.25
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1-((2-(ethylamino)ethyl)amino)-2-methyl-3-(4-(trifluoromethyl)phenyl)- 
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.1) 
Obtained from 5.1 (0.278 g, 0.72 mmol, 1.0 
equiv.), N-ethylethylenediamine (0.376 mL, 
1.44 mmol, 2.0 equiv.) and triethylamine 
(0.20 mL, 1.44 mmol, 2.0 equiv.) as a 
yellow/orange solid (0.204 g, 65 %); m.p. 174 
– 177 °C; Rf 0.31 (5 % MeOH-DCM); 1H NMR 
(400 MHz, CDCl3) δ 8.35 (d, J = 8.4 Hz, 1H, 
ArH9), 7.98 (d, J = 8.2 Hz, 1H, ArH6), 7.79 (d, 
J = 8.1 Hz, 2H, ArH13,15), 7.57 – 7.50 (m, 3H, ArH7,12,16), 7.34 (t, J = 8.4 Hz, 
1H, ArH8), 6.02 (s, 1H, NH), 3.50 (t, J = 5.4 2H, H17), 3.04 – 2.98 (m, 2H, H18), 
2.80 (q, J = 7.1 Hz, 2H, H19), 2.15 (s, 3H, H21), 1.22 (t, J = 7.1 Hz, 3H, H20); 
13C NMR (101 MHz, CDCl3) δ 151.8, 148.3, 147.6, 145.4, 140.5, 131.4, 131.1, 
129.3, 128.7, 126.2, 125.8, 125.8, 122.5, 121.1, 119.9, 115.8, 115.0, 104.4, 
92.3, 48.5, 46.5, 43.6, 15.3, 15.0; HPLC-MS (APCI/ESI): Purity = 96%, tR = 
3.53 min, MS: m/z 438.2 [M+H]+. 
 
1-((2-(ethylamino)ethyl)amino)-2-fluoro-3-(4-(trifluoromethyl)phenyl)- 
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.2) 
Obtained from 5.2 (0.240 g, 0.59 mmol, 1.0 
equiv.), N-ethylethylenediamine (0.29 mL, 
1.18 mmol, 2.0 equiv.) and triethylamine 
(0.16 mL, 1.18 mmol, 2.0 equiv.) as a yellow 
solid (0.050 g, 19 %); m.p. 281 - 286 °C; Rf 
0.17 (8 % MeOH-DCM); 1H NMR (400 MHz, 
DMSO-d6) δ 7.74 (d, J = 8.2 Hz, 2H, H6,9), 
7.49 (d, J = 8.1 Hz, 4H, H12,13,15,16), 7.19 – 
7.14 (m, 2H, H7,8), 4.52 (t, J = 9.5 Hz, 2H, H17), 4.12 (t, J = 9.5 Hz, 2H, H18), 
3.65 (q, J = 7.2 Hz, 2H, H19), 1.27 (t, J = 7.2 Hz, 3H, H20); 13C NMR (101 MHz, 
MeOD) δ 148.3, 144.9, 143.8, 143.7, 143.6, 143.4, 134.3, 134.0, 131.8, 
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131.4, 131.1, 129.9, 125.1, 125.0, 122.9, 122.6, 122.4, 110.9, 96.1, 49.1 42.5, 
42.4, 11.9; 19F NMR (377 MHz, MeOD) δ -64.48, -166.23; HPLC-MS 
(APCI/ESI): Purity = 99%, tR = 3.75 min, MS: m/z 442.1 [M+H]+. 
 
1-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-2-methyl-3-(4-(trifluoro-
methyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.3) 
 Obtained from 5.1 (0.215 g, 0.56 mmol, 
1.0 equiv.), 1-(2-aminoethyl)-3-pyrroldinol 
(0.109 g, 0.84 mmol, 1.5 equiv.) and 
triethylamine (0.15 mL, 1.11 mmol, 2.0 
equiv.) as an orange/brown solid (0.150 g, 
56 %); m.p. 236 – 238 °C; Rf 0.26 (5 % 
MeOH-DCM); 1H NMR (400 MHz, DMSO-
d6) δ 8.40 (d, J = 8.4 Hz, 1H, ArH9), 7.96 
(d, J = 7.8 Hz, 2H, ArH13,15), 7.86 (d, J = 
7.8 Hz, 1H, ArH6), 7.71 (d, J = 7.8 Hz, 2H, ArH12,16), 7.57 (ddd, J = 8.4, 7.6, 
1.2 Hz, 1H, ArH7), 7.39 (ddd, J = 8.4, 7.6, 1.2 Hz, 1H, ArH8), 4.71 - 4.64 (m, 
1H, H20), 4.10 (s, 1H, NH), 3.48 (t, J = 5.7 Hz, 2H, H17), 2.66 (t, J = 5.7 Hz, 
2H, H18), 2.57 – 2.48 (m, 2H, H21),  2.29 – 2.23 (m, 2H, H22), 2.07 (s, 3H, H23), 
1.92 - 182 (m, 1H, H19), 1.55 – 1.43 (m, 1H, H19); 13C NMR (101 MHz, DMSO-
d6) δ 152.0, 149.5, 148.0, 145.3, 141.8, 130.2, 130.0, 129.7, 129.0, 126.3, 
126.1, 126.1, 123.2, 121.1, 119.1, 116.8, 116.3, 105.8, 90.1, 62.5, 56.1, 55.3, 
52.3, 45.8, 34.9, 15.2; HPLC-MS (APCI/ESI): Purity = 99%, tR = 3.56 min, MS: 
m/z 480.2 [M+H]+. 
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2-fluoro-1-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-3-(4-
(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(6.4)  
Obtained from 5.2 (0.614 g, 1.50 mmol, 1.0 
equiv.), 1-(2-aminoethyl)-3-pyrroldinol 
(0.294 g, 2.26 mmol, 1.5 equiv.) and 
triethylamine (0.42 mL, 3.00 mmol, 2.0 
equiv.) as a yellow solid (0.323 g, 44 %); 
m.p. 265 - 267 °C; Rf 0.34 (5 % MeOH-
DCM); 1H NMR (400 MHz, DMSO-d6) δ 
8.54 (d, J = 8.4 Hz, 1H, ArH9), 7.96 (d, J = 
8.0 Hz, 2H, ArH13,15), 7.86 (d, J = 8.0 Hz, 2H, ArH12, 16), 7.82 (d, J = 8.4 Hz, 
1H, ArH6), 7.55 (t, J = 8.4 Hz, 1H, ArH7), 7.34 (t, J = 8.4 Hz, 1H, ArH8), 4.35 – 
4.25 (m, 1H, H20), 3.92 – 3.82 (m, 2H, H17), 3.01 – 2.95 (m, 2H, H18), 2.94 – 
2.89 (m, 2H, H21), 2.72 – 2.66 (m, 2H, H22), 2.08 – 2.02 (m, 1H, H19), 1.74 – 
1.65 (m, 1H, H19).  13C NMR (101 MHz, DMSO-d6) δ 147.2, 145.7, 141.3, 
141.1, 136.5, 133.1, 130.9, 130.2, 130.1, 126.2, 125.9, 125.9, 123.2 120.7, 
118.7, 117.2, 117.2, 115.5, 62.5, 55.4, 55.4, 52.4, 44.3, 44.2, 34.7; HPLC-MS 
(APCI/ESI): Purity = 99%, tR = 3.51 min, MS: m/z 484.2 [M+H]+. 
 
1-((2-(3-hydroxypyrrolidin-1-yl)ethyl)amino)-3-(4-(trifluoromethyl)phenyl)-
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.5) 
Obtained from 5.3 (0.300 g, 0.81 mmol, 
1.0 equiv.), 1-(2-aminoethyl)-3-pyrroldinol 
(0.158 g, 1.21 mmol, 1.5 equiv.) and 
triethylamine (0.20 mL, 1.61 mmol, 2.0 
equiv.) as a yellow solid (0.122 g, 32 %); 
m.p. 267 - 269 °C; Rf 0.24 (5 % MeOH-
DCM); 1H NMR (400 MHz, DMSO-d6) δ 
8.43 (d, J = 8.4 Hz, 1H, ArH9), 8.00 – 7.93 
(m, 4H, ArH12,13,15,16), 7.89 – 7.86 (m, 1H, 
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ArH6), 7.60 (ddd, J = 8.4, 7.2, 0.9 Hz, 1H, ArH7), 7.41 (ddd, J = 8.4, 7.2, 0.9 
Hz, 1H, ArH8), 6.29 (s, 1H, H2), 4.71 (s, 1H, NH), 4.37 – 4.28 (m, 1H, H20), 
3.72 (t, J = 6.3 Hz, 2H, H17), 3.05 – 3.02 (m, 2H, H18), 3.00 – 2.94 (m, 2H, 
H21), 2.79 – 2.68 (m, 2H, H22), 2.16 – 2.02 (m, 1H, H19), 1.78 – 1.66 (m, 1H, 
H19); 13C NMR (101 MHz, DMSO-d6) δ 150.6, 149.3, 149.0, 145.4, 141.9, 
130.4, 130.1, 128.3, 126.4, 126.1, 126.1, 125.9, 123.2, 121.2, 119.1, 117.6, 
115.0, 90.8, 82.8, 62.6, 55.4, 53.3, 52.6, 49.1, 34.7; HPLC-MS (APCI/ESI): 
Purity = 99%, tR = 3.38 min, MS: m/z 466.2 [M+H]+.  
 
7,8-dichloro-1-((2-(ethylamino)ethyl)amino)-2-fluoro-3-(4-
(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(6.7)  
Obtained from 5.4 (0.600 g, 1.31 mmol, 
1.0 equiv.), N-ethylethylenediamine (0.28 
mL, 2.62 mmol, 2.0 equiv.) and 
triethylamine (0.36 mL, 2.62 mmol, 2.0 
equiv.) as a yellow solid (0.185 g, 28 %); 
m.p 332 - 338 °C; Rf 0.08 (20 % MeOH-
DCM); 1H NMR (400 MHz, DMSO-d6) δ 
7.73 (d, J = 7.8 Hz, 4H, ArH6, 9,15,16), 7.45 
(d, J = 7.8 Hz, 2H, ArH12,16) , 4.51 (t, J = 9.4 Hz, 2H, H17), 4.12 (t, J = 9.4 Hz, 
2H, H18), 3.65 (q, J = 7.1 Hz, 2H, H19), 1.27 (t, J = 7.1 Hz, 3H, H20); 13C NMR 
(101 MHz, DMSO-d6) δ 148.4, 143.7, 143.4, 143.1, 143.0, 134.9, 133.7, 
131.5, 130.6, 130.3, 130.0, 129.7 (2C), 125.8, 125.7, 125.0, 123.0, 120.2, 
95.9, 48.8, 48.0, 42.6, 13.3; HPLC-MS (APCI/ESI): Purity= 98%, tR = 4.74 
min, MS: m/z 510.1 [M+H]+. 
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7,8-dichloro-1-((2-(ethylamino)ethyl)amino)-3-(4-(trifluoromethyl)phenyl)-
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.8)  
Obtained from 5.5 (0.413 g, 0.93 mmol, 
1.0 equiv.), N-ethylethylenediamine (0.20 
mL, 1.87 mmol, 2.0 equiv.) and 
triethylamine (0.26 mL, 1.87 mmol, 2.0 
equiv.) as a yellow solid (0.112 g, 24 %); 
m.p 266 - 268 °C; Rf 0.40 (8 % MeOH-
DCM); 1H NMR (400 MHz, DMSO-d6) δ 
8.95 (s, 1H, ArH9), 7.87 (d, J = 8.4 Hz, 2H, ArH13,15), 7.84 (d, J = 8.4 Hz, 2H, 
ArH12,16), 7.71 (s, 1H, ArH6), 5.72 (s, 1H, H2), 3.58 (t, J = 6.2 Hz, 2H, H17), 
3.25 (t, J = 6.2 Hz, 2H, H18), 3.05 (q, J = 7.3 Hz, 2H, H19), 1.24 (t, J = 7.3 Hz, 
3H, H20); 13C NMR (101 MHz, DMSO-d6) δ 154.3, 152.7, 148.0, 145.5, 143.8, 
130.4, 129.6 (2C), 129.5, 129.0, 126.2, 125.7, 125.7, 123.7, 120.6, 119.8, 
117.7, 116.6, 91.8, 48.1, 44.8, 42.8, 12.0; HPLC-MS (APCI/ESI): Purity= 99%, 
tR = 4.29 min, MS: m/z 492.1 [M+H]+.   
1-((2-(ethylamino)ethyl)amino)-2,7,8-trifluoro-3-(4-(trifluoromethyl)-
phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.9)  
Obtained from 5.6 (0.579 g, 1.36 mmol, 
1.0 equiv.), N-ethylethylenediamine (0.29 
mL, 2.72 mmol, 2.0 equiv.) and 
triethylamine (0.38 mL, 2.72 mmol, 2.0 
equiv.) as a yellow solid (0.033 g, 5 %); 
m.p 253 - 260 °C; Rf 0.13 (20 % MeOH-
DCM); 1H NMR (400 MHz, DMSO-d6) δ 
7.70 (d, J = 8.0 Hz, 2H, ArH13,15), 7.42 (d, 
J = 8.0 Hz, 2H, ArH12,16), 7.10 (t, J = 9.9 Hz, 2H, ArH6,9), 4.46 (t, 2H, J = 9.2, 
H17), 4.02 (t, J = 9.2 Hz, 2H, H18), 3.57 (q, J = 7.1 Hz, 2H, H19), 1.23 (t, J = 7.1 
Hz, 3H, H20); 13C NMR (101 MHz, DMSO-d6) δ 156.2, 148.9, 144.3, 142.4, 
142.3, 138.2, 133.6, 130.5 (2C), 128.9, 128.6, 128.3, 126.1, 125.0 (2C), 
123.4, 102.2 (2C), 89.0, 48.4, 47.7, 42.5, 13.1; HPLC-MS (APCI/ESI): Purity= 
99%, tR = 4.14 min, MS: m/z 478.1 [M+H]+. 
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1-((2-(ethylamino)ethyl)amino)-7,8-difluoro-3-(4-(trifluoromethyl)phenyl)-
benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.10)  
Obtained from 5.7 (0.250 g, 0.61 mmol, 
1.0 equiv.), N-ethylethylenediamine (0.13 
mL, 1.22 mmol, 2.0 equiv.) and 
triethylamine (0.17 mL, 1.22 mmol, 2.0 
equiv.) as a yellow solid (0.200 g, 71 %); 
m.p 212 - 215 °C; Rf 0.41 (20 % MeOH-
DCM); 1H NMR (400 MHz, DMSO-d6) δ 
8.75 (dd, J = 11.5, 8.0 Hz, 1H, ArH9), 7.84 
(m, 4H, ArH12,13,15,16), 7.52 (dd, J = 11.5, 8.0 Hz, 1H, ArH6), 5.68 (s, 1H, ArH2), 
3.56 (t, J = 6.1 Hz, 2H, H17), 3.23 (t, J = 6.1 Hz, 2H, H18), 3.01 (q, J = 7.2 Hz, 
2H, H19), 1.22 (t, J = 7.2 Hz, 3H, H20); 13C NMR (101 MHz, DMSO-d6) δ 153.6, 
152.2, 147.9, 146.8, 146.7, 143.9, 142.6, 141.6, 141.5, 129.6, 129.5, 125.7, 
125.7, 120.5, 105.2, 105.0, 103.2, 103.0, 91.0, 48.2, 44.7, 42.9, 12.4; HPLC-
MS (APCI/ESI): Purity= 99%, tR = 3.84 min, MS: m/z 460.2 [M+H]+.   
 
2-benzyl-1-((2-(ethylamino)ethyl)amino)-3-methylbenzo[4,5]imidazo- 
[1,2a]pyridine-4-carbonitrile (6.12)  
Obtained from 5.8 (0.293 g, 0.88 mmol, 1.0 
equiv.), N-ethylethylenediamine (0.19 mL, 1.80 
mmol, 2.0 equiv.) and triethylamine (0.25 mL, 
1.77 mmol, 2.0 equiv.) as an orange solid 
(0.023 g, 7 %); m.p. 174 – 176 °C; Rf 0.10 (5 
% MeOH-DCM); 1H NMR (400 MHz, DMSO-
d6) δ 8.28 (dt, J = 8.4, 1.0 Hz, 1H, ArH9), 7.83 
(dt, J = 8.4, 1.0 Hz, 1H, ArH6), 7.53 (ddd, J = 8.4, 7.1, 1.1 Hz, 1H, ArH7), 7.36 
– 7.29 (m, 3H, ArH8,13,17), 7.24 – 7.16 (m, 3H, ArH14,15,16), 4.27 (s, 2H, H11), 
3.21 (t, J = 5.9 Hz, 2H, H19), 2.66 (t, J = 5.9 Hz, 2H, H20), 2.49 (s, 3H, H18), 
2.45 (q, J = 7.1 Hz, 2H, H21), 0.97 (t, J = 7.1 Hz, 3H, H22); 13C NMR (101 MHz, 
DMSO-d6) δ 151.0, 149.1, 148.3, 145.1, 139.8, 129.4, 129.1 (3C), 128.1, 
126.8 (2C), 126.1, 120.9, 119.0, 117.0, 116.5, 110.3, 49.0, 47.2, 43.5, 32.0, 
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19.8, 15.7; HPLC-MS (APCI/ESI): Purity = 99%, tR = 3.22 min, m/z 384.2 
[M+H]+.  
2-(4-chlorobenzyl)-1-((2-(ethylamino)ethyl)amino)-3-methylbenzo-
[4,5]imidazo [1,2-a]pyridine-4-carbonitrile (6.13)  
Obtained from 5.9 (0.600 g, 1.64 mmol, 1.0 
equiv.), N-ethylethylenediamine (0.35 mL, 
3.28 mmol, 2.0 equiv.) and triethylamine 
(0.45 mL, 3.28 mmol, 2.0 equiv.) as a yellow 
solid (0.137 g, 20 %); m.p. 189 – 191 °C; Rf 
0.33 (5 % MeOH-DCM); 1H NMR (400 MHz, 
DMSO-d6) δ 8.30 (d, J = 8.4 Hz, 1H, ArH9), 
7.83 (d, J = 8.4 Hz, 1H, ArH6), 7.53 (t, J = 8.4 Hz, 1H, ArH7), 7.37 – 7.32 (m, 
3H, ArH8,14,16), 7.20 (d, J = 8.4 Hz, 2H, ArH13,17), 4.26 (s, 2H, H11), 3.22 – 3.19 
(m, 2H, H19), 2.67 (t, J = 5.9 Hz, 2H, H20), 2.49 – 2.43 (m, 5H, H18,21), 0.97 (t, J 
= 7.1 Hz, 3H, H22); 13C NMR (101 MHz, DMSO-d6) δ 155.9, 150.9, 149.7, 
148.1, 138.7, 131.6, 131.2, 129.8, 129.2, 127.4, 122.2, 121.0, 119.1, 115.8, 
115.7, 102.5, 101.1, 89.7, 48.7, 45.9, 44.1, 31.2, 18.7, 13.7; HPLC-MS 
(APCI/ESI): Purity = 99%, tR = 3.71 min, MS: m/z 418.1 [M+H]+. 
2-(3-chlorobenzyl)-1-((2-(ethylamino)ethyl)amino)-3-methylbenzo-[4,5]imi 
dazo[1,2-a]pyridine-4-carbonitrile (6.14)  
Obtained from 5.10 (0.600 g, 1.64 mmol, 1.0 
equiv.), N-ethylethylenediamine (0.35 mL, 3.28 
mmol, 2.0 equiv.) and triethylamine (0.46 mL, 
3.28 mmol, 2.0 equiv.) as an orange solid 
(0.212 g, 31 %); m.p. 162 – 166 °C; Rf 0.23 (5 
% MeOH-DCM); 1H NMR (400 MHz, DMSO-
d6) δ 8.28 (d, J = 8.0 Hz, 1H, ArH9), 7.83 (d, J 
= 8.0 Hz, 1H, ArH6), 7.53 (ddd, J = 8.0, 7.1, 1.1 Hz, 1H, ArH7), 7.36 – 7.27 (m, 
4H, ArH8,14,15,17), 7.11 (dt, J = 7.4, 1.5 Hz, 1H, ArH13), 4.28 (s, 2H, H11), 3.21 
(t, J = 6.0 Hz, 2H, H19), 2.65 (t, J = 6.0 Hz, 2H, H20), 2.47 (s, 3H, H18), 2.44 (q, 
J = 7.5 Hz, 2H, H21), 0.97 (t, J = 7.5 Hz, 3H, H22); 13C NMR (101 MHz, DMSO-
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d6) δ 150.8, 149.2, 148.4, 145.2, 142.6, 133.8, 130.9 (2C), 129.5, 128.1, 
126.8 (2C), 126.0, 120.8, 119.0, 117.0, 116.5, 109.4, 49.1, 47.2, 43.5, 31.8, 
19.8, 15.6; HPLC-MS (APCI/ESI): Purity = 99%, tR = 3.60 min, MS: m/z 418.1 
[M+H]+. 
2-(2-chlorobenzyl)-1-((2-(ethylamino)ethyl)amino)-3-methylbenzo-
[4,5]imidazo[1,2-a]pyridine-4-carbonitrile (6.15)  
Obtained from 5.11 (0.450 g, 1.23 mmol, 1.0 
equiv.), N-ethylethylenediamine (0.26 mL, 
2.46 mmol, 2.0 equiv.) and triethylamine (0.34 
mL, 2.46 mmol, 2.0 equiv.) as a yellow solid 
(0.103 g, 20 %); m.p 200 - 202 °C; Rf 0.44 (5 
% MeOH-DCM); 1H NMR (400 MHz, DMSO-
d6) δ 8.33 (d, J = 8.4 Hz, 1H, ArH9), 7.85 (d, J 
= 8.4 Hz, 1H, ArH6), 7.57 – 7.51 (m, 2H, 
ArH7,14), 7.36 (ddd, J = 8.4, 7.1, 1.2 Hz, 1H, ArH8), 7.29 (td, J = 7.6, 1.7 Hz, 
1H, ArH15), 7.21 (td, J = 7.6, 1.4 Hz, 1H, ArH16), 6.91 (d, J = 7.6 Hz, 1H, 
ArH17), 4.29 (s, 2H, H11), 3.23 (t, J = 5.9 Hz, 2H, H19), 2.69 (t, J = 5.9 Hz, 2H, 
H20), 2.44 (q, J = 7.1 Hz, 2H, H21), 2.40 (s, 3H, H18), 0.96 (t, J = 7.1 Hz, 3H, 
H22); 13C NMR (101 MHz, DMSO-d6) δ 151.0, 149.2, 148.4, 145.3, 137.0, 
133.7, 129.8, 129.5, 129.0, 128.6, 128.0, 126.1 (2C), 120.9, 119.1, 116.8, 
116.4, 108.4, 49.0, 47.2, 43.4, 30.6, 19.4, 15.5; HPLC-MS (APCI/ESI): Purity= 
99%, tR = 3.49 min, MS: m/z 418.1 [M+H]+.   
 
General procedure for the synthesis of target compounds 6.6 and 6.11 
4-Amino-α-diethylamino-o-cresol (2.0 equiv.) was added to a stirring solution 
of the appropriate chlorinated intermediate (1.0 equiv.) and triethylamine (2.0 
equiv.) in THF (4.0 mL) and DMF (0.15 mL). The solution was heated in the 
microwave at 80°C for 40-60 minutes. The solvent was removed in vacuo. 
The reaction mixture was diluted in DCM, washed with water, brine and dried 
over anhydrous magnesium sulphate. The solution was concentrated in vacuo  
and the residue was purified using Biotage Isolera One® column 
chromatography, SiO2 (25 g cartridge), EtOAc/Hexane, with fractions being 
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collected at 280nm and monitored at 254nm. Fractions were combined, the 
solvent was removed in vacuo and the resulting solid was further purified by 
recrystallization from acetone. 
 
 
1-((3-((diethylamino)methyl)-4-hydroxyphenyl)amino)-2-fluoro-3-(4-
(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(6.6)  
Obtained from 5.2 (0.198 g, 0.51 mmol, 1.0 
equiv.), 4-amino-α-diethylamino-o-cresol 
(0.197 g, 1.02 mmol, 2.0 equiv.) and 
triethylamine (0.14 mL, 1.02 mmol, 2.0 equiv.) 
as a yellow solid (0.033 g, 11 %); m.p 275 - 
280 °C; Rf 0.49 (20 % MeOH-DCM); 1H NMR 
(400 MHz, DMSO-d6) δ 8.66 (d, 1H, ArH9), 
7.88 (d, J = 8.1 Hz, 2H, ArH13,15), 7.74 (d, J = 
8.1 Hz, 2H, ArH12,16), 7.59 (d, J = 7.8 Hz, 1H, 
ArH6), 7.37 (t, J = 7.8 Hz, 1H, ArH7), 7.10 (t, J 
= 7.8 Hz, 1H, ArH8), 6.92 – 6.81 (m, 2H, 
ArH18,22), 6.75 (d, J = 8.5 Hz, 1H, ArH21), 4.02 (s, 2H, H23), 2.92 (q, J = 8.0 Hz, 
4H, H24,26), 1.15 (t, J = 8.0 Hz, 3H, H25,27); 13C NMR (101 MHz, DMSO-d6) δ 
152.4, 151.4, 149.3, 144.8, 144.7, 142.8, 137.8, 131.5, 130.9, 129.7, 129.4, 
126.0, 125.6 (2C), 124.9, 123.5, 123.3, 122.5, 119.8, 118.9, 117.1, 116.2, 
115.7, 106.5, 98.3, 52.1, 46.7, 31.1, 29.8, 9.6; HPLC-MS (APCI/ESI): Purity= 
99%, tR = 3.98 min, MS: m/z 548.1 [M+H]+. 
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1-((3-((diethylamino)methyl)-4-hydroxyphenyl)amino)-7,8-difluoro-3-(4-
(trifluoromethyl)phenyl)benzo[4,5]imidazo[1,2-a]pyridine-4-carbonitrile 
(6.11) 
Obtained from 5.7 (0.405 g, 0.99 mmol, 
1.0 equiv.), 4-amino-α-diethylamino-o-
cresol (0.386 g, 1.99 mmol, 2.0 equiv.) 
and triethylamine (0.28 mL, 1.99 mmol, 
2.0 equiv.) as a yellow solid (0.145 g, 26 
%); m.p 284 - 288 °C; Rf 0.65 (20 % 
MeOH-DCM); 1H NMR (400 MHz, DMSO-
d6) δ 8.76 (dd, J = 11.5, 8.7 Hz, 1H, ArH9), 
7.80 (d, J = 8.2 Hz, 2H, ArH13,15), 7.69 (d, 
J = 8.2 Hz, 2H, ArH12,16), 7.55 (dd, J = 
11.5, 8.7 Hz, 1H, ArH6), 7.06 (d, J = 2.6 
Hz, 1H, ArH18), 6.99 (dd, J = 8.5, 2.6 Hz, 1H, ArH22), 6.86 (d, J = 8.5 Hz, 1H, 
ArH21), 5.59 (s, 1H, ArH2), 4.08 (s, 2H, H23), 2.97 (q, J = 7.2 Hz, 4H, H24,26), 
1.16 (t, J = 7.2 Hz, 6H, H25,27); 13C NMR (101 MHz, DMSO-d6) δ 153.8, 151.0, 
149.3, 149.2, 147.8, 146.8, 144.9, 143.8, 141.8, 141.6, 129.4, 129.2, 126.2, 
126.0, 125.8, 125.8, 125.1, 123.3, 120.3, 116.7, 105.0, 104.8, 103.5, 103.3, 
92.6, 55.4, 51.9, 47.0, 25.6, 9.6; HPLC-MS (APCI/ESI): Purity= 97%, tR = 4.15 
min, MS: m/z 566.2 [M+H]+. 
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4.3 Assay Protocols 
 
4.3.1.	Antiplasmodial activity assay  
	
This procedure was designed for use with culture adapted P. falciparum 
strains and clinical isolates. On one 96-well plate, 6 drugs were tested in 
duplicate. Standard strains used were P. falciparum, NF54 (sensitive to all 
known drugs) and Plasmodium falciparum, K1 (chloroquine and 
pyrimethamine resistant).  
Antimalarial drugs were dissolved in DMSO at 10mg/mL. If insoluble, other 
solvents were used according to the recommendations of the supplier. For the 
assays, 4X fresh dilutions of all drugs in screening medium were prepared. 
Blood smears of stock cultures of the two strains were prepared and 
parasitemia was determined (parasitemia < 3% was not used).  Drug stock 
solutions were diluted with screening medium to the right start concentrations.  
Serial drug dilutions were prepared with a multichannel pipette. 100 μL was 
taken from wells of row B and transferred, after gentle mixing, to wells of row 
C. After mixing, 100 μL was transferred from wells of row C to wells of row D 
and so forth to row H. The 100 μL removed from wells of row H were 
discarded. A two-fold serial dilution of drugs was thus obtained. For too active 
compounds the highest concentration was appropriately lowered. Wells of 
rows A served as controls without drug.  
100 μL of infected blood (parasitemia of 0.3%, 2.5% hematocrit) were added 
to all wells with a multipette. Only the control wells (A9-12) received 
uninfected blood of 2.5% hematocrit. The plates were incubated in an 
incubation chamber at 37°C in an atmosphere containing the special gas 
mixture (93% N2, 4% CO2, 3% O2).  
After 48 hours 50 μL [3H]-hypoxanthine (= 0.5 μCi) solution was added to 
each well of the plate. The plates were incubated for another 24 hours. The 
plates were then harvested with a BetaplateTM cell harvester (Wallac, Zurich, 
Switzerland), which transferred the red blood cells onto a glass fiber filter and 
washed with distilled water. The dried filters were inserted into a plastic foil 
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with 10 mL of scintillation fluid and counted in a BetaplateTM liquid 
scintillation counter (Wallac, Zurich, Switzerland). The results were recorded 
as counts per minute (cpm) per well at each drug concentration. Data was 
transferred into a graphic programme (e.g. EXCEL) and expressed as 
percentage of the untreated controls. The 50% inhibitory concentration (IC50) 
value was evaluated by Logit regression analysis.  
Definition of test score: no activity: IC50 > 1000 ng/mL; low activity: IC50 50-
1000 ng/mL; good activity: IC50 < 50 ng/mL. Chloroquine and artesunate are 
used for each assay as positive controls.  
 
4.3.2 Cytotoxicity assay 
	
Test samples were screened for in vitro cytotoxicity against a mammalian cell-
line, Chinese Hamster Ovarian (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT)-assay. The MTT-assay is used as a 
colorimetric assay for cellular growth and survival. The tetrazolium salt, MTT, 
was used to measure all growth and chemosensitivity. The test samples were 
tested in triplicate on one occasion.  
The test samples were prepared to a 20 mg/mL stock solution in 100% 
DMSO. Test compounds were stored at -20°C until use. Dilutions were 
prepared on the day of the experiment. Emetine was used as the reference 
drug in all experiments. The initial concentration of emetine was 100 μg/mL, 
which was serially diluted in complete medium with 10-fold dilutions to give 6 
concentrations, the lowest being 0.001 μg/mL. The same dilution technique 
was applied to all the test samples. The highest concentration of solvent to 
which the cells were exposed to had no measurable effect on the cell viability 
(data not shown). The 50% inhibitory concentration (IC50) values were 
obtained from full dose-response curves, using a non-linear dose-response 
curve fitting analysis via GraphPad Prism v.4 software. 
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4.3.3	β-Hematin inhibition assay 
 
 
Stock solutions of controls and test compounds were made to 20 mM in 
DMSO. A solution containing water/305.5 μM NP40/DMSO at a v/v ratio of 
70%/20%/10%, respectively was added to every well in columns 1-11 while 
140 μL of water and 40 μL of 305.5 μM NP40 were added to column 12 to 
mediate the formation of β-hematin. Twenty microliters of drug (20 mM) was 
added to column 12 and 100 μL of this solution serially diluted to column 2, 
and column 1 was left as a blank (0 μM of compound). In case the compound 
was colored (for instance AQ), a pre-reading of the plate was done by 
measuring absorbance at 405 nm on a SpectraMax plate reader. A 178.8 μL 
aliquot of hematin stock was suspended in 20 mL of a 1 M acetate buffer, pH 
4.9 and 100 μL of this hematin suspension added into each well. Plates were 
then incubated for ±5 hours at 37°C after which 32 μL of pyridine solution 
(20% water, 20% acetone, 10% 2M HEPES buffer (pH 7.4), 50% pyridine) 
was added, followed by addition of 60 μL of acetone to all wells. Plates were 
again read at 405 nm and IC50 values plotted in GraphPad.  
 
4.3.4 Microsomal metabolic stability assay 
 
The metabolic stability of the compounds was assessed in mouse liver 
microsomes, using the one point assay described in the Standard Operating 
Procedure 4.2_NL_20120829 TO assay (pre-clinical pharmacology laboratory 
at Groote Schuur Hospital).  
 
Briefly, the metabolic stability was determined after 30 minutes incubation of 
the compounds with mouse liver microsomes. After protein precipitation, the 
supernatant was analyzed by LC-MS-MS (4000 Q-TRAP AB Sciex) with MRM 
methods using a Phenomenex Kinetex PFP, 2.1 mm x 50 mm, 2.6 µm 
particles. The incubations were performed in triplicates and controls were also 
included (propranolol, midazolam and MMV390048). Results were reported 
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as % remaining after 30 minutes incubation and as predicted half-life, using 
the Obach’s formula. 
 
4.3.5 Kinetic solubility assay 
 
All target compounds were assessed for kinetic solubility using a 96-well clear 
polystyrene plate. The compounds were dissolved in HPLC grade DMSO to 
make 10 mM stock solutions. The pre-dilution plate was prepared by making 
serial dilutions of the stock solution in DMSO, in triplicate, to obtain 
concentrations ranging from 0.25 to 8.0 mM.  
 
From the pre-dilution plate, the assay plate is prepared by making secondary 
dilutions in DMSO and 0.01M pH 7.4 PBS, also in triplicate. These dilutions 
are made such that the final volume in each assay plate well is 200 μL and 
the concentrations of the wells range from 0 to 200 μM. The plates were then 
covered and left to incubate at room temperature for 2 hours. Absorbance 
measurements were taken at 620 nm with a SpectraMax 340PC mircoplate 
reader (Molecular Devices, Sunnydale, CA). The analysis wavelength of 620 
nm was chosen since few samples are known to absorb at this wavelength 
and thus it minimizes the chance of false readings resulting from absorbance 
by the compound in solution. A plot of absorbance vs. concentration is used to 
identify the limit of solubility. 
 
4.3.6 Equilibrium solubility assay 
 
Aqueous solubility was measured using the DMSO-dry down method, 
adapted from Zhou et al.76 Briefly, the high and medium calibration standards 
(220 µM, 100 µM) in duplicate, as well as the samples (200 µM) in triplicate, 
were added to a 96-well plate, from a 10mM stock solution in DMSO. DMSO 
was then evaporated in a MiVac sample concentrator (SP Scientific, Cape 
Town, South Africa) operated at full vacuum, 37°C, for two hours. DMSO was 
then added to the standards, and after vortexing the plate, the high standard 
was used to prepare a low (11 µM) calibration standard in DMSO. Phosphate 
buffered saline (pH 7.4) was added to the sample wells and the plate was 
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incubated for 24 hours at 25°C with shaking. The plate was then centrifuged 
at 2500 g for 30 minutes and the supernatants transferred to another plate for 
analysis.  
 
Aqueous solubility was determined from UV peak areas of the samples 
relative to the standards using best-fit calibration curves in Microsoft Excel 
2013. HPLC-DAD analysis was performed using an Agilent 1200 Rapid 
Resolution HPLC, coupled with an Agilent 1200 diode array detector 
(ABSciex, Johannesburg, South Africa). For elution, 0.1% formic acid in water 
and 0.1% formic acid in acetonitrile were used as mobile phases A and B 
respectively. A Kinetex C18 (50mm x 2.1 mm), packed with 2.6 μM fused-core 
particles (Separations, Johannesburg, South Africa) was used for the 
chromatography. Agilent Chemstation was used for instrument control and 
data processing. 
 
4.3.7 Single crystal XRD analysis 
 
Single-crystal X-ray diffraction data were collected on a Bruker KAPPA APEX 
II DUO diffractometer using graphite-monochromated Mo-Ka radiation (c = 
0.71073 Å). Data collection was carried out at 173(2) K. Temperature was 
controlled by an Oxford Cryostream cooling system (Oxford Cryostat). Cell 
refinement and data reduction were performed using the program SAINT77. 
The data were scaled and absorption correction performed using SADABS78.  
The structure was solved by direct methods using SHELXS-9778 and refined 
by full-matrix least-squares methods based on F2 using SHELXL-201478 and 
using the graphics interface program X-Seed79,80. The programs X-Seed and 
POV-Ray81 were both used to prepare molecular graphic images.  
 
4.3.8 DFT calculations 
 
All calculations were performed using Gaussian 09 and Jaguar82 from the 
Schrödinger Suite 2012. Visualizations were performed using the graphical 
interface Maestro 7.9.83  
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